日本臨牀　80/増刊5　免疫性神経疾患（第2版）

出版社： 日本臨牀社
発行日： 2022-05-31
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 免疫性神経疾患（第2版）
電子書籍版： 2022-05-31 （第2版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

22,000 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

22,000 円(税込)

購入する

目次

  • 特集　免疫性神経疾患（第2版）
    　　　―基礎・臨床の最新知見―

    序文

    I．総　論
    　１．免疫性神経疾患の研究・診断・治療の動向
    　２．知っておきたい免疫性神経疾患の遺伝的要因
    　３．知っておきたい免疫性神経疾患の疫学・環境要因
    　４．知っておきたい自然免疫の免疫性神経疾患への関わり
    　５．知っておきたい獲得免疫の免疫性神経疾患への関わり
    　６．腸内環境の神経変性疾患への関わり
    　７．知っておきたいグリアの免疫性神経疾患への関わり
    　８．知っておきたい免疫性神経疾患に対する分子標的療法のリスク・ベネフィットバランス
    　９．知っておきたい免疫性神経疾患治療薬のワクチン接種への影響
    　10．診療に役立つ免疫性中枢神経疾患の画像検査とその解釈
    　11．診療に役立つ免疫性末梢神経疾患の画像検査とその解釈
    　12．診療に役立つ免疫性中枢神経疾患の臨床神経生理検査とその解釈
    　13．診療に役立つ免疫性末梢神経疾患の臨床神経生理検査とその解釈
    　14．診療に役立つ免疫性神経筋接合部疾患・筋疾患の臨床神経生理検査とその解釈
    　15．診療に役立つ免疫性神経疾患の血液バイオマーカーとその解釈
    　16．診療に役立つ免疫性神経疾患の髄液検査とその解
    　17．診療に役立つ免疫性神経疾患の自己抗体測定法とその解釈
    　18．診療に役立つ免疫性神経疾患の神経・筋病理検査とその解釈

    II．中枢神経脱髄疾患
    　１．多発性硬化症の病態・病理
    　２．MSの病型と経過
    　３．MSの臨床・検査
    　４．MSの障害度評価とQOL評価
    　５．MSの最新の治療戦略オーバービュー
    　６．再発寛解型MSの抗B細胞療法の意義とメカニズム
    　７．二次性進行型多発性硬化症の治療とモニター
    　８．一次進行型MSの治療の現状と展望
    　９．視神経脊髄炎スペクトルム(NMOSD)の病理・病態
    　10．NMOSDの臨床・検査と診断基準・障害度評価
    　11．NMSDOの最新の治療戦略オーバービュー
    　12．NMOSDの抗補体抗体療法
    　13．NMOSDの抗サイトカイン療法
    　14．NMOSDの抗B細胞療法
    　15．MOGAD（抗MOG抗体関連疾患）
    　16．Tumefactive MS,Baló病
    　17．急性散在性脳脊髄炎(ADEM)
    　18．MS/NMOSDの疾患修飾薬に関連した進行性多巣性白質脳症(PML)

    III．末梢神経脱髄疾患
    　１．Guillain-Barré 症候群の診断と治療update
    　２．フィッシャー症候群
    　３．CIDPの病型と診断
    　４．CIDPの治療戦略
    　５．自己免疫性ノドパチー
    　６．中枢末梢連合脱髄症
    　７．抗MAG抗体陽性ニューロパチー

    IV．脱髄以外の中枢神経免疫疾患
    　１．自己免疫性脳炎・脳症のオーバービュー
    　２．自己免疫性てんかん
    　３．自己免疫性運動異常症
    　４．Rasmussen脳炎
    　５．小児急性脳症
    　６．橋本脳症
    　７．自己免疫性小脳失調症
    　８．Bickerstaff脳幹脳炎
    　９． Primary angiitis of the CNS (PACNS) / Primary CNS vasculitis (PCNSV)
    　10．肥厚性硬膜炎
    　11．HTLV-1-associated myelopathy (HAM)
    　12．アトピー性脊髄炎,Hopkins症候群
    　13．Stiff person sydrome,Progressive encephalomyelitis with rigidity and myoclonus
    　14．Acute encephalomyeloradiculoneuritisと抗中性糖脂質抗体
    　15．CLIPPERS，Susac症候群

    V．脱髄以外の末梢神経免疫疾患
    　１．Crow-深瀬症候群（POEMＳ症候群）
    　２．血管炎性症候群・好酸球性多発血管炎性肉芽腫症
    　３．Isaacs症候群/neuromyotonia/抗VGKC複合体抗体関連疾患
    　４．自己免疫性自律神経節障害、急性自律神経性感覚性ニューロパチー
    　５．Neuropathic pain（Small fiber neuropathy）/
    　　　　painful trigeminal neuropathyと抗Plexin D1抗体

    VI．免疫性神経筋接合部疾患
    　１．免疫性神経筋接合部疾患における自己抗体と病態における意義
    　２．重症筋無力症(MG)の疫学・遺伝的背景・環境因子
    　３．MGの臨床と診断基準
    　４．MGの最新の治療戦略オーバービュー
    　５．MGの抗補体療法
    　６．Lambert-Eaton筋無力症候群

    VII．免疫性筋疾患
    　１．免疫性筋疾患における自己抗体オバービュー　　
    　２．多発筋炎,皮膚筋炎,amyopathic dermatomyositis
    　３．封入体筋炎
    　４．壊死性筋炎・筋症
    　５．筋炎の鑑別診断：好酸球性筋膜炎とリウマチ性多発筋痛症

    VIII．内科疾患や腫瘍に伴う神経免疫疾患
    　１．Neuropsychiatric SLE
    　２．神経ベーチェット病/神経スウィート病
    　３．シェーグレン症候群による神経障害
    　４．神経サルコイドーシス
    　５．傍腫瘍性神経症候群
    　６．神経リンパ腫症
    　７．IgG4関連疾患に伴う神経障害

    IX．トピックス・今知りたいこと
    　１．新型コロナウイルス感染症（COVID‑19）と神経免疫疾患
    　２．免疫チェックポイント阻害薬と神経免疫疾患
    　３．小児の免疫性神経疾患に対する免疫療法のポイント
    　４．慢性ウイルス感染症キャリアの免疫性神経疾患に対する治療のポイント
    　５．妊娠・授乳中の免疫性神経疾患の治療方針
    　６．免疫性神経疾患におけるshared decision making
    　７．免疫性神経疾患の支援制度と医療経済

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 総論

P.16 掲載の参考文献
1) International Multiple Sclerosis Genetics Consortium : Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 365 : eaav7188, 2019.
PubMed
2) International Multiple Sclerosis Genetics Consortium : Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. Cell 175 : 1679-1687.e7, 2018.
 
3) Isobe N, et al : An ImmunoChip study of multiple sclerosis risk in African Americans. Brain 138 : 1518-1530, 2015.
PubMed
4) Sato S, et al : Copy number variations in multiple sclerosis and neuromyelitis optica. Ann Neurol 78 : 762-774, 2015.
PubMed
5) Masterman T, et al : HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 48 : 211-219, 2000.
PubMed
6) Nakamura Y, et al ; Japan Multiple Sclerosis Genetics Consortium : Latitude and HLA-DRB1*04 : 05 independently influence disease severity in Japanese multiple sclerosis : a cross-sectional study. J Neuroinflammation 13 : 239, 2016.
PubMed
7) Shinoda K, et al : HLA-DRB1*04 : 05 allele is associated with intracortical lesions on 3-dimensional double inversion recovery images in Japanese patients with multiple sclerosis. Mult Scler 24 : 710-720, 2018.
PubMed
8) Watanabe M, et al : Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod. J Neuroinflammation 17 : 206, 2020.
PubMed
9) Matsushita T, et al : Genetic factors for susceptibility to and manifestations of neuromyelitis optica. Ann Clin Transl Neurol 7 : 2082-2093, 2020.
PubMed
10) Sakoda A, et al : Environmental risk factors for multiple sclerosis in Japanese people. Mult Scler Relat Disord 38 : 101872, 2020.
PubMed
11) Takewaki D, et al : Alterations of the gut ecological and functional microenvironment in different stages of multiple sclerosis. Proc Natl Acad Sci U S A 117 : 22402-22412, 2020.
PubMed
12) Hayashi F, et al : A new clustering method identifies multiple sclerosis-specific T-cell receptors. Ann Clin Transl Neurol 8 : 163-176, 2021.
PubMed
13) Glanville J, et al : Identifying specificity groups in the T cell receptor repertoire. Nature 547 : 94-98, 2017.
 
14) Raveney BJ, et al : Eomesodermin-expressing T-helper cells are essential for chronic neuroinflammation. Nat Commun 6 : 8437, 2015.
PubMed
15) Raveney BJ, et al : Involvement of cytotoxic Eomes-expressing CD4+ T cells in secondary progressive multiple sclerosis. Proc Natl Acad Sci U S A 118 : e2021818118, 2021.
PubMed
16) Zhao Y, et al : Oligodendroglial connexin 47 regulates neuroinflammation upon autoimmune demyelination in a novel mouse model of multiple sclerosis. Proc Natl Acad Sci U S A 117 : 2160-2169, 2020.
 
17) Une H, et al : Brain gray matter astroglia-specific connexin 43 ablation attenuates spinal cord inflammatory demyelination. J Neuroinflammation 18 : 126, 2021.
PubMed
18) Liddelow SA, et al : Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541 : 481-487, 2017.
PubMed
19) Hammond TR, et al : Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes. Immunity 50 : 253-271.e6, 2019.
 
20) Keren-Shaul H, et al : A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. Cell 169 : 1276-1290.e17, 2017.
 
21) Masuda T, et al : Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature 566 : 388-392, 2019.
PubMed
22) Van Hove H, et al : A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment. Nat Neurosci 22 : 1021-1035, 2019.
PubMed
23) Galli E, et al : GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis. Nat Med 25 : 1290-1300, 2019.
 
24) Sand IK, et al : Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler 20 : 1654-1657, 2014.
 
25) Lorscheider J, et al : Defining secondary progressive multiple sclerosis. Brain 139 : 2395-2405, 2016.
PubMed
26) Kremenchutzky M, et al : The natural history of multiple sclerosis : a geographically based study 9 : observations on the progressive phase of the disease. Brain 129 : 584-594, 2006.
PubMed
27) University of California, San Francisco MS-EPIC Team ; Cree BAC, et al : Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol 85 : 653-666, 2019.
PubMed
28) Kappos L, et al : Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol 77 : 1132-1140, 2020.
 
29) Watanabe M, et al : Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology 93 : e1299-e1311, 2019.
PubMed
30) Aktas O, et al : Serum Glial Fibrillary Acidic Protein : A Neuromyelitis Optica Spectrum Disorder Biomarker. Ann Neurol 89 : 895-910, 2021.
PubMed
31) Kira JI : Anti-Neurofascin 155 Antibody-Positive Chronic Inflammatory Demyelinating Polyneuropathy/Combined Central and Peripheral Demyelination : Strategies for Diagnosis and Treatment Based on the Disease Mechanism. Front Neurol 12 : 665136, 2021.
PubMed
32) Ogata H, et al : Optic, trigeminal, and facial neuropathy related to anti-neurofascin 155 antibody. Ann Clin Transl Neurol 7 : 2297-2309, 2020.
PubMed
33) Hashimoto Y, et al : Chronic Inflammatory Demyelinating Polyneuropathy With Concurrent Membranous Nephropathy : An Anti-paranode and Podocyte Protein Antibody Study and Literature Survey. Front Neurol 9 : 997, 2018.
PubMed
34) Fujii T, et al : A Novel Autoantibody against Plexin D1 in Patients with Neuropathic Pain. Ann Neurol 84 : 208-224, 2018.
 
35) Fujii T, et al : Painful trigeminal neuropathy associated with anti-Plexin D1 antibody. Neurol Neuroimmunol Neuroinflamm 7 : e819, 2020.
PubMed
36) Fujii T, et al : Antiplexin D1 Antibodies Relate to Small Fiber Neuropathy and Induce Neuropathic Pain in Animals. Neurol Neuroimmunol Neuroinflamm 8 : e1028, 2021.
PubMed
37) Shibuya K, et al : Reconstruction magnetic resonance neurography in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 77 : 333-337, 2015.
PubMed
38) Maggi P, et al : Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies. Ann Neurol 83 : 283-294, 2018.
PubMed
39) Shinoda K, et al : Contribution of cortical lesions to cognitive impairment in Japanese patients with multiple sclerosis. Sci Rep 10 : 5228, 2020.
PubMed
40) Frischer JM, et al : Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol 78 : 710-721, 2015.
PubMed
41) Absinta M, et al : Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo. JAMA Neurol 76 : 1474-1483, 2019.
PubMed
42) Ighani M, et al : No association between cortical lesions and leptomeningeal enhancement on 7-Tesla MRI in multiple sclerosis. Mult Scler 26 : 165-176, 2020.
PubMed
43) Lorscheider J, et al : Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology 89 : 1050-1059, 2017.
PubMed
44) Kappos L, et al : Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND) : a double-blind, randomised, phase 3 study. Lancet 391 : 1263-1273, 2018.
PubMed
45) Montalban X, et al : Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 376 : 209-220, 2017.
PubMed
P.22 掲載の参考文献
1) Compston A, et al : Multiple sclerosis. Lancet 372 : 1502-1517, 2008.
PubMed
2) Thompson AJ, et al : Multiple sclerosis. Lancet 391 : 1622-1636, 2018.
PubMed
3) Isobe N, Oksenberg JR : Genetic studies of multiple sclerosis and neuromyelitis optica : Current status in European, African American and Asian populations. Clin Exp Neuroimmunol 5 : 61-68, 2014.
 
4) Yoshimura S, et al : Genetic and Infectious Profiles of Japanese Multiple Sclerosis Patients. PLoS One 7 : e48592, 2012.
PubMed
5) International Multiple Sclerosis Genetics Consortium ; De Jager PL, et al : Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 365 : eaav7188, 2019.
PubMed
6) Olsson T, et al : Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol 13 : 25-36, 2017.
PubMed
7) Hedstrom AK, et al : Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain 134 : 653-664, 2011.
PubMed
8) Sundqvist E, et al : Epstein-Barr virus and multiple sclerosis : interaction with HLA. Genes Immun 13 : 14-20, 2012.
PubMed
9) Hedstrom AK, et al : Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. Neurology 82 : 865-872, 2014.
PubMed
10) Hayashi F, et al : A new clustering method identifies multiple sclerosis-specific T-cell receptors. Ann Clin Transl Neurol 8 : 163-176, 2021.
PubMed
11) Watanabe M, et al : Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod. J Neuroinflammation 17 : 206, 2020.
PubMed
12) Alvarenga MP, et al : Neuromyelitis optica is an HLA associated disease different from Multiple Sclerosis : a systematic review with meta-analysis. Sci Rep 11 : 152, 2021.
PubMed
13) Estrada K, et al : A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica. Nat Commun 9 : 1929, 2018.
 
14) Matsushita T, et al : Genetic factors for susceptibility to and manifestations of neuromyelitis optica. Ann Clin Transl Neurol 7 : 2082-2093, 2020.
PubMed
15) Alborzian Deh Sheikh A, et al : A Guillain-Barre syndrome-associated SIGLEC10 rare variant impairs its recognition of gangliosides. J Autoimmun 116 : 102571, 2021.
PubMed
16) Van den Bergh PYK, et al : European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint Task Force-Second revision. Eur J Neurol 28 : 3556-3583, 2021.
PubMed
17) Ogata H, et al : Unique HLA haplotype associations in IgG4 anti-neurofascin 155 antibody-positive chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 339 : 577139, 2020.
PubMed
18) Iijima M, et al : Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP. Neurology 73 : 1348-1352, 2009.
 
19) Penova M, et al : Genome wide association study of HTLV-1-associated myelopathy/tropical spastic paraparesis in the Japanese population. Proc Natl Acad Sci U S A 118 : e2004199118, 2021.
PubMed
20) Gilhus NE, et al : Myasthenia gravis. Nat Rev Dis Primers 5 : 30, 2019.
PubMed
21) Rider LG, et al : Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. Arthritis Rheum 41 : 710-719, 1998.
PubMed
22) Rothwell S, et al : Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Ann Rheum Dis 75 : 1558-1566, 2016.
PubMed
23) Oyama M, et al : HLA-DRB1 allele and autoantibody profiles in Japanese patients with inclusion body myositis. PLoS One 15 : e0237890, 2020.
PubMed
P.27 掲載の参考文献
1) The Multiple Sclerosis International Federation : Atlas of MS, 3rd edition : Mapping multiple sclerosis around the world, 2020.
 
2) 吉良潤一, ほか : 第5回多発性硬化症・視神経脊髄炎全国臨床疫学調査結果 第2報. 令和2 (2020) 年度厚生労働科学研究費補助金 (難治性疾患政策研究事業) 神経免疫疾患のエビデンスに基づく診断基準・重症度分類・ガイドラインの妥当性と患者QOLの検証分担研究報告書, p29-31, 2021.
 
3) Belbasis L, et al : Environmental factors and risk of multiple sclerosis : Findings from meta-analyses and Mendelian randomization studies. Mult Scler 26 : 397-404, 2020.
PubMed
4) Hernan MA, et al : Cigarette smoking and the progression of multiple sclerosis. Brain 128 : 1461-1465, 2005.
PubMed
5) Ramanujam R, et al : Effect of Smoking Cessation on Multiple Sclerosis Prognosis. JAMA Neurol 72 : 1117-1123, 2015.
PubMed
6) Sakoda A, et al : Environmental risk factors for multiple sclerosis in Japanese people. Mult Scler Relat Disord 38 : 101872, 2020.
PubMed
7) Miyake S, Yamamura T : Gut environmental factors and multiple sclerosis. J Neuroimmunol 329 : 20-23, 2019.
PubMed
8) Haase S, et al : Dietary fatty acids and susceptibility to multiple sclerosis. Mult Scler 24 : 12-16, 2018.
PubMed
9) Langer-Gould A, et al : Seafood, fatty acid biosynthesis genes, and multiple sclerosis susceptibility. Mult Scler 26 : 1476-1485, 2020.
PubMed
10) Mori M, et al : Worldwide prevalence of neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 89 : 555-556, 2018.
PubMed
11) Hor JY, et al : Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol 11 : 501, 2020.
PubMed
12) Papp V, et al : Worldwide Incidence and Prevalence of Neuromyelitis Optica : A Systematic Review. Neurology 96 : 59-77, 2021.
PubMed
13) Bizzoco E, et al : Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 256 : 1891-1898, 2009.
PubMed
14) Yoshimura S, et al : Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status. J Neurol Neurosurg Psychiatry 84 : 29-34, 2013.
PubMed
15) Varrin-Doyer M, et al : Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 72 : 53-64, 2012.
PubMed
16) Pereira WL, et al : Epidemiological, clinical, and immunological characteristics of neuromyelitis optica : A review. J Neurol Sci 355 : 7-17, 2015.
PubMed
17) Kieseier BC, et al : Immune-mediated neuropathies. Nat Rev Dis Primers 4 : 31, 2018.
PubMed
18) Shahrizaila N, et al : Guillain-Barre syndrome. Lancet 397 : 1214-1228, 2021.
PubMed
19) Marini A, et al : Neurologic Adverse Events of Immune Checkpoint Inhibitors : A Systematic Review. Neurology 96 : 754-766, 2021.
PubMed
20) Iijima M, et al : Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry 79 : 1040-1043, 2008.
PubMed
21) Van den Bergh PYK, et al : European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint Task Force-Second revision. J Peripher Nerv Syst 26 : 242-268, 2021.
PubMed
22) Salari N, et al : Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment : a systematic review and meta-analysis. J Transl Med 19 : 516, 2021.
 
23) 吉川弘明, ほか : 重症筋無力症の全国疫学調査 二次調査による臨床像解析. 令和1 (2019) 年度 厚生労働科学研究費補助金 (難治性疾患政策研究事業) 神経免疫疾患のエビデンスによる診断基準・重症度分類・ガイドラインの妥当性と患者QOLの検証分担研究報告書, p22-25, 2020.
 
24) HTLV-1関連脊髄症 (HAM) 診療ガイドライン 2019 (厚生労働省「HAMならびにHTLV-1陽性難治性疾患に関する国際的な総意形成を踏まえた診療ガイドラインの作成」研究班, 「HTLV-1関連脊髄症 (HAM) 診療ガイドライン 2019」作成委員会編, 日本神経学会, ほか監), 南江堂, 2019.
 
25) Yamauchi J, et al : An update on human T-cell leukemia virus type I (HTLV-1) -associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers. Pharmacol Ther 218 : 107669, 2021.
 
P.34 掲載の参考文献
1) Flannagan RS, et al : The cell biology of phagocytosis. Annu Rev Pathol 7 : 61-98, 2012.
PubMed
2) Brinkmann V, et al : Neutrophil extracellular traps kill bacteria. Science 303 : 1532-1535, 2004.
PubMed
3) Wartha F, Henriques-Normark B : ETosis : a novel cell death pathway. Sci Signal 1 : pe25, 2008.
 
4) Takeuchi O, Akira S : Pattern recognition receptors and inflammation. Cell 140 : 805-820, 2010.
PubMed
5) Patel S : Danger-Associated Molecular Patterns (DAMPs) : the Derivatives and Triggers of Inflammation. Curr Allergy Asthma Rep 18 : 63, 2018.
 
6) Lamkanfi M, Dixit VM : Mechanisms and functions of inflammasomes. Cell 157 : 1013-1022, 2014.
PubMed
7) Shin JI, et al : Inflammasomes and autoimmune and rheumatic diseases : A comprehensive review. J Autoimmun 103 : 102299, 2019.
PubMed
8) Deerhake ME, et al : Pattern Recognition Receptors in Multiple Sclerosis and Its Animal Models. Front Immunol 10 : 2644, 2019.
PubMed
9) Reu P, et al : The Lifespan and Turnover of Microglia in the Human Brain. Cell Rep 20 : 779-784, 2017.
PubMed
10) Swirski FK, et al : Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325 : 612-616, 2009.
PubMed
11) Muller WA : Transendothelial migration : unifying principles from the endothelial perspective. Immunol Rev 273 : 61-75, 2016.
PubMed
12) Mamdouh Z, et al : Transcellular migration of leukocytes is mediated by the endothelial lateral border recycling compartment. J Exp Med 206 : 2795-2808, 2009.
PubMed
13) Miller DH, et al : A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348 : 15-23, 2003.
PubMed
14) Mills CD, et al : M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 164 : 6166-6173, 2000.
 
15) Mantovani A, et al : Macrophage polarization : tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23 : 549-555, 2002.
PubMed
P.41 掲載の参考文献
1) Fraussen J, et al : Targets of the humoral autoimmune response in multiple sclerosis. Autoimmun Rev 13 : 1126-1137, 2014.
PubMed
2) Glatigny S, Bettelli E : Experimental Autoimmune Encephalomyelitis (EAE) as Animal Models of Multiple Sclerosis (MS). Cold Spring Harb Perspect Med 8 : a028977, 2018.
PubMed
3) Martin R, et al : Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis. Eur J Immunol 46 : 2078-2090, 2016.
PubMed
4) Geginat J, et al : Plasticity of human CD4 T cell subsets. Front Immunol 5 : 630, 2014.
PubMed
5) Venken K, et al : Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol Med 16 : 58-68, 2010.
PubMed
6) Hiltensperger M, Korn T : The Interleukin (IL) -23/T helper (Th) 17 Axis in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. Cold Spring Harb Perspect Med 8 : a029637, 2018.
PubMed
7) Sakaguchi S, et al : Regulatory T Cells and Human Disease. Annu Rev Immunol 38 : 541-566, 2020.
PubMed
8) Vinuesa CG, et al : Follicular Helper T Cells. Annu Rev Immunol 34 : 335-368, 2016.
PubMed
9) Constantinescu CS, Gran B : The essential role of T cells in multiple sclerosis : a reappraisal. Biomed J 37 : 34-40, 2014.
PubMed
10) Veroni C, Aloisi F : The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue : A Central Issue in Multiple Sclerosis Pathogenesis. Front Immunol 12 : 665718, 2021.
PubMed
11) Rawlings DJ, et al : Altered B cell signalling in autoimmunity. Nat Rev Immunol 17 : 421-436, 2017.
PubMed
12) Negron A, et al : Ectopic Lymphoid Follicles in Multiple Sclerosis : Centers for Disease Control? Front Neurol 11 : 607766, 2020.
PubMed
13) Cancro MP : Age-Associated B Cells. Annu Rev Immunol 38 : 315-340, 2020.
PubMed
14) Raveney BJ, et al : Eomesodermin-expressing T-helper cells are essential for chronic neuroinflammation. Nat Commun 6 : 8437, 2015.
PubMed
15) Raveney BJE, et al : Involvement of cytotoxic Eomes-expressing CD4+ T cells in secondary progressive multiple sclerosis. Proc Natl Acad Sci U S A 118 : e2021818118, 2021.
PubMed
P.46 掲載の参考文献
1) Noto D, Miyake S : Gut dysbiosis and multiple sclerosis. Clin Immunol 235 : 108380, 2022.
PubMed
2) Miyake S, et al : Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters. PLoS One 10 : e0137429, 2015.
PubMed
3) Mizuno M, et al : The dual role of short fatty acid chains in the pathogenesis of autoimmune disease models. PLoS One 12 : e0173032, 2017.
PubMed
4) Haase S, et al : Dietary fatty acids and susceptibility to multiple sclerosis. Mult Scler 24 : 12-16, 2018.
PubMed
5) Chen T, et al : Butyrate suppresses demyelination and enhances remyelination. J Neuroinflammation 16 : 165, 2019.
PubMed
6) Takewaki D, et al : Alterations of the gut ecological and functional microenvironment in different stages of multiple sclerosis. Proc Natl Acad Sci USA 117 : 22402-22412, 2020.
PubMed
7) Planas R, et al : GDP-l-fucose synthase is a CD4+ T cell-specific autoantigen in DRB3*02 : 02 patients with multiple sclerosis. Sci Transl Med 10 : eaat4301, 2018.
PubMed
8) Miyauchi E, et al : Gut microorganisms act together to exacerbate inflammation in spinal cords. Nature 585 : 102-106, 2020.
PubMed
9) Gate D, et al : CD4+ T cells contribute to neurodegeneration in Lewy body dementia. Science 374 : 868-874, 2021.
PubMed
10) Sulzer D, et al : T cells from patients with Parkinson's disease recognize α-synuclein peptides. Nature 546 : 656-661, 2017.
 
11) Uemura N, et al : Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve. Mol Neurodegener 13 : 21, 2018.
 
12) Pfeiffer RF : Gastrointestinal Dysfunction in Parkinson's Disease. Curr Treat Options Neurol 20 : 54, 2018.
PubMed
13) Scheperjans F, et al : Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord 30 : 350-358, 2015.
PubMed
14) Nishiwaki H, et al : Meta-Analysis of Gut Dysbiosis in Parkinson's Disease. Mov Disord 35 : 1626-1635, 2020.
PubMed
15) Barrett JC, et al : Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 40 : 955-962, 2008.
PubMed
P.55 掲載の参考文献
1) Kettenmann H, Verkhratsky A : Neuroglia : the 150 years after. Trends Neurosci 31 : 653-659, 2008.
PubMed
2) von Bartheld CS, et al : The search for true numbers of neurons and glial cells in the human brain : A review of 150 years of cell counting. J Comp Neurol 524 : 3865-3895, 2016.
 
3) Schulz C, et al : A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336 : 86-90, 2012.
 
4) Chu T, et al : Dynamic glial response and crosstalk in demyelination-remyelination and neurodegeneration processes. Neural Regen Res 16 : 1359-1368, 2021.
PubMed
5) 越智博文 : 多発性硬化症の疫学-多発性硬化症は本当に増えているか. BRAIN and NERVE 72 : 467-484, 2020.
 
6) Patrikios P, et al : Remyelination is extensive in a subset of multiple sclerosis patients. Brain 129 : 3165-3172, 2006.
 
7) Wilkins A, Scolding N : Protecting axons in multiple sclerosis. Mult Scler 14 : 1013-1025, 2008.
PubMed
8) Boyd A, et al : Insufficient OPC migration into demyelinated lesions is a cause of poor remyelination in MS and mouse models. Acta Neuropathol 125 : 841-859, 2013.
PubMed
9) O'Loughlin E, et al : Microglial Phenotypes and Functions in Multiple Sclerosis. Cold Spring Harb Perspect Med 8 : a028993, 2018.
 
10) Skripuletz T, et al : Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination. Brain 136 : 147-167, 2013.
PubMed
11) Trapp BD, et al : Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338 : 278-285, 1998.
PubMed
12) Schultz V, et al : Acutely damaged axons are remyelinated in multiple sclerosis and experimental models of demyelination. Glia 65 : 1350-1360, 2017.
PubMed
13) Lassmann H, Bradl M : Multiple sclerosis : experimental models and reality. Acta Neuropathol 133 : 223-244, 2017.
PubMed
14) Reynolds R, et al : The response of NG2-expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS. J Neurocytol 31 : 523-536, 2002.
 
15) Hampton DW, et al : An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss. J Neuroimmunol 201-202 : 200-211, 2008.
 
16) Mecha M, et al : Viral models of multiple sclerosis : neurodegeneration and demyelination in mice infected with Theiler's virus. Prog Neurobiol 101-102 : 46-64, 2013.
 
17) Lindner M, et al : Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination. Neurosci Lett 453 : 120-125, 2009.
PubMed
18) Chu T, et al : Dynamic response of microglia/macrophage polarization following demyelination in mice. J Neuroinflammation 16 : 188, 2019.
PubMed
19) McMurran CE, et al : Toxin-Based Models to Investigate Demyelination and Remyelination. Methods Mol Biol 1936 : 377-396, 2019.
 
20) Ransohoff RM : A polarizing question : do M1 and M2 microglia exist? Nat Neurosci 19 : 987-991, 2016.
 
21) Miron VE : Microglia-driven regulation of oligodendrocyte lineage cells, myelination, and remyelination. J Leukoc Biol 101 : 1103-1108, 2017.
PubMed
22) Lloyd AF, et al : Central nervous system regeneration is driven by microglia necroptosis and repopulation. Nat Neurosci 22 : 1046-1052, 2019.
PubMed
23) Voskuhl RR, et al : Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. J Neurosci 29 : 11511-11522, 2009.
PubMed
24) Keough MB, et al : An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination. Nat Commun 7 : 11312, 2016.
PubMed
25) Anderson MA, et al : Astrocyte scar formation aids central nervous system axon regeneration. Nature 532 : 195-200, 2016.
PubMed
26) Liddelow SA, et al : Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541 : 481-487, 2017.
PubMed
27) Tanuma N, et al : Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. Acta Neuropathol 112 : 195-204, 2006.
 
28) Brambilla R, et al : Astrocytes play a key role in EAE pathophysiology by orchestrating in the CNS the inflammatory response of resident and peripheral immune cells and by suppressing remyelination. Glia 62 : 452-467, 2014.
PubMed
29) Omari KM, et al : CXC chemokine receptors on human oligodendrocytes : implications for multiple sclerosis. Brain 128 : 1003-1015, 2005.
PubMed
30) Calderon TM, et al : A role for CXCL12 (SDF-1alpha) in the pathogenesis of multiple sclerosis : regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. J Neuroimmunol 177 : 27-39, 2006.
PubMed
31) Crawford AH, et al : Remyelination : the true regeneration of the central nervous system. J Comp Pathol 149 : 242-254, 2013.
PubMed
32) Dai X, et al : The trophic role of oligodendrocytes in the basal forebrain. J Neurosci 23 : 5846-5853, 2003.
PubMed
33) Zeis T, et al : The immunomodulatory oligodendrocyte. Brain Res 1641 (Pt A) : 139-148, 2016.
 
34) Kirby L, et al : Oligodendrocyte precursor cells present antigen and are cytotoxic targets in inflammatory demyelination. Nat Commun 10 : 3887, 2019.
PubMed
35) Moll NM, et al : Imaging correlates of leukocyte accumulation and CXCR4/CXCL12 in multiple sclerosis. Arch Neurol 66 : 44-53, 2009.
PubMed
36) Miron VE, et al : M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci 16 : 1211-1218, 2013.
PubMed
37) Voss EV, et al : Characterisation of microglia during de- and remyelination : can they create a repair promoting environment? Neurobiol Dis 45 : 519-528, 2012.
 
38) Stankoff B, et al : Ciliary neurotrophic factor (CNTF) enhances myelin formation : a novel role for CNTF and CNTF-related molecules. J Neurosci 22 : 9221-9227, 2002.
PubMed
39) Thummler K, et al : Polarizing receptor activation dissociates fibroblast growth factor 2 mediated inhibition of myelination from its neuroprotective potential. Acta Neuropathol Commun 7 : 212, 2019.
PubMed
40) Yamasaki R : Connexins in health and disease. Clin Exp Neuroimmunol 9 (Suppl 1) : 30-36, 2018.
 
41) Masaki K, et al : Connexin 43 astrocytopathy linked to rapidly progressive multiple sclerosis and neuromyelitis optica. PLoS One 8 : e72919, 2013.
PubMed
42) Fang M, et al : Connexin 30 Deficiency Attenuates Chronic but Not Acute Phases of Experimental Autoimmune Encephalomyelitis Through Induction of Neuroprotective Microglia. Front Immunol 9 : 2588, 2018.
 
43) Une H, et al : Brain gray matter astroglia-specific connexin 43 ablation attenuates spinal cord inflammatory demyelination. J Neuroinflammation 18 : 126, 2021.
PubMed
44) Zhao Y, et al : Oligodendroglial connexin 47 regulates neuroinflammation upon autoimmune demyelination in a novel mouse model of multiple sclerosis. Proc Natl Acad Sci U S A 117 : 2160-2169, 2020.
 
P.63 掲載の参考文献
1) Goodin DS : The epidemiology of multiple sclerosis : insights to disease pathogenesis. Handb Clin Neurol 122 : 231-266, 2014.
PubMed
2) Polman CH, et al : A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354 : 899-910, 2006.
PubMed
3) Butzkueven H, et al : Long-term safety and effectiveness of natalizumab treatment in clinical practice : 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry 91 : 660-668, 2020.
 
4) Major EO, et al : Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis : a decade of lessons learned. Lancet Neurol 17 : 467-480, 2018.
PubMed
5) 中道一生, 西條政幸 : I. 神経・筋 進行性多巣性白質脳症. 生体の科学 71 : 420-421, 2020.
 
6) Sorensen PS, et al : Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 18 : 143-152, 2012.
PubMed
7) Ho PR, et al : Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis : a retrospective analysis of data from four clinical studies. Lancet Neurol 16 : 925-933, 2017.
PubMed
8) Clerico M, et al : Extending the Interval of Natalizumab Dosing : Is Efficacy Preserved? Neurotherapeutics 17 : 200-207, 2020.
PubMed
9) Ryerson LZ, et al : Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology 93 : e1452-e1462, 2019.
PubMed
10) Hauser SL, et al : Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med 383 : 546-557, 2020.
PubMed
11) Laroni A, et al : COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments. Mult Scler 27 : 2126-2136, 2021.
PubMed
12) Sahraian MA, et al : Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Mult Scler Relat Disord 46 : 102472, 2020.
PubMed
13) Samjoo IA, et al : Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis : a network meta-analysis. J Comp Eff Res 9 : 1255-1274, 2020.
PubMed
14) Wiendl H, et al : Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program. Mult Scler 27 : 719-728, 2021.
PubMed
15) Lennon VA, et al : A serum autoantibody marker of neuromyelitis optica : distinction from multiple sclerosis. Lancet 364 : 2106-2112, 2004.
PubMed
16) Lennon VA, et al : IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202 : 473-477, 2005.
 
17) Wingerchuk DM, et al : The spectrum of neuromyelitis optica. Lancet Neurol 6 : 805-815, 2007.
PubMed
18) Wingerchuk DM, et al : International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85 : 177-189, 2015.
PubMed
19) Akaishi T, et al : Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence. Neurol Neuroimmunol Neuroinflamm 7 : e640, 2020.
PubMed
20) Pittock SJ, et al : Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med 381 : 614-625, 2019.
PubMed
21) Yamamura T, et al : Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med 381 : 2114-2124, 2019.
PubMed
22) Traboulsee A, et al : Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder : a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 19 : 402-412, 2020.
 
23) Chen D, et al : Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases : Insights from Preclinical Studies. J Clin Med 5 : 107, 2016.
 
24) Cree BAC, et al : Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum) : a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 394 : 1352-1363, 2019.
PubMed
25) Gilhus NE : Myasthenia Gravis. N Engl J Med 375 : 2570-2581, 2016.
PubMed
26) Howard JF Jr, et al : Safety and efficacy of eculizumab in anti-acetylcholine receptor antibodypositive refractory generalised myasthenia gravis (REGAIN) : a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16 : 976-986, 2017.
 
27) Muppidi S, et al : Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 60 : 14-24, 2019.
PubMed
P.68 掲載の参考文献
1) Greenbook. Chapter 14a-COVID-19-SARS-CoV-2. 16 Sep 2021.
 
2) 日本脳卒中学会, 日本血栓止血学会 : アストラゼネカ社COVID-19ワクチン接種後の血小板減少を伴う血栓症の診断と治療の手引き・第2版. 2021年6月. [http://www.jsth.org/wordpress/wp-content/uploads/2021/06/TTS%E6%89%8B%E5%BC%95%E3%81%8Dver.2.3.pdf]
 
3) Shapiro Ben David S, et al : Rate of Recurrent Guillain-Barre Syndrome After mRNA COVID-19 Vaccine BNT162b2. JAMA Neurol 78 : 1409-1411, 2021.
PubMed
4) Finsterer J : Exacerbating Guillain-Barre syndrome eight days after vector-based COVID-19 vaccination. Case Rep Infect Dis 2021 : 3619131, 2021.
PubMed
5) 荒井元美 : COVID-19ワクチン接種を受けたSjogren症候群患者に生じたGuillain-Barre症候群と後根神経節炎. 脳神経内科 95 : 692-694, 2021.
 
6) Di Filippo M, et al : mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. J Neurol Neurosurg Psychiatry, 2021. (DOI : org/10.1136/jnnp-2021-327200)
PubMed
7) Reder AT, et al : COVID-19 in Patients with Multiple Sclerosis : Associations with Disease-Modifying Therapies. CNS Drugs 35 : 317-330, 2021.
PubMed
8) Sormani MP, et al : Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol 89 : 780-789, 2021.
PubMed
9) Achiron A, et al : Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord 14 : 1-8, 2021.
PubMed
10) Sormani MP, et al : Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine 72 : 103581, 2021.
PubMed
11) Tanaka M, Fujihara K : Difference of anti-viral immunity induced by two mRNA vaccines : implications in MS patients treated with anti-CD20 depleting therapy. Clin Exp Neuroimmunol 13 : 5-6, 2021.
 
12) Chow RM, et al : The COVID-19 vaccine and interventional procedures : Exploring the relationship between steroid administration and subsequent vaccine efficacy. Pain Pract 21 : 966-973, 2021.
PubMed
13) Furer V, et al : Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population : a multicentre study. Ann Rheum Dis 80 : 1330-1338, 2021.
PubMed
14) Kageyama T, et al : Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan. Clin Microbiol Infect 27 : 1861.e1-1861.e5, 2021.
 
P.77 掲載の参考文献
1) Miki Y : Magnetic resonance imaging diagnosis of demyelinating diseases : an update. Clin Exp Neuroimmunol 10 (Suppl 1) : 32-48, 2019.
 
2) Hagiwara A, et al : Analysis of White Matter Damage in Patients with Multiple Sclerosis via a Novel In Vivo MR Method for Measuring Myelin, Axons, and G-Ratio. AJNR Am J Neuroradiol 38 : 1934-1940, 2017.
 
3) Fujita S, et al : 3D Quantitative Synthetic MRI in the Evaluation of Multiple Sclerosis Lesions. AJNR Am J Neuroradiol 42 : 471-478, 2021.
PubMed
4) Thompson AJ, et al : Diagnosis of multiple sclerosis : 2017 revisions of the McDonald criteria. Lancet Neurol 17 : 162-173, 2018.
PubMed
5) 渡邊充, 吉良潤一 : 診断基準 (McDonald 2017 基準). Clinical Neuroscience 36 : 1283-1285, 2018.
 
6) Miki Y, et al : Isolated U-fiber involvement in MS : preliminary observations. Neurology 50 : 1301-1306, 1998.
PubMed
7) Absinta M, et al : Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo. JAMA Neurol 76 : 1474-1483, 2019.
PubMed
8) Wattjes MP, Barkhof F : Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Curr Opin Neurol 27 : 260-270, 2014.
PubMed
9) 三木幸雄 : 多発性硬化症のMRI-診断ツール, バイオマーカー, 副作用モニタリングツールとしての役割. BRAIN and NERVE 72 : 493-508, 2020.
 
10) 宍戸-原由紀子, 鹿戸将史 : 進行性多巣性白質脳症 (PML) のMRI画像診断-MRIが捉えた, 伸展する脱髄病変の病理. BRAIN and NERVE 72 : 973-986, 2020.
 
11) Wingerchuk DM, et al : International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85 : 177-189, 2015.
PubMed
12) Tatekawa H, et al : Imaging Differences between Neuromyelitis Optica Spectrum Disorders and Multiple Sclerosis : A Multi-Institutional Study in Japan. AJNR Am J Neuroradiol 39 : 1239-1247, 2018.
PubMed
13) Kim HJ, et al : MRI characteristics of neuromyelitis optica spectrum disorder : an international update. Neurology 84 : 1165-1173, 2015.
PubMed
14) Jarius S, et al : MOG encephalomyelitis : international recommendations on diagnosis and antibody testing. J Neuroinflammation 15 : 134, 2018.
PubMed
15) Marignier R, et al : Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 20 : 762-772, 2021.
PubMed
16) Krupp LB, et al : International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders : revisions to the 2007 definitions. Mult Scler 19 : 1261-1267, 2013.
 
17) Callen DJ, et al : Role of MRI in the differentiation of ADEM from MS in children. Neurology 72 : 968-973, 2009.
PubMed
18) Varadan B, et al : Acute hemorrhagic leukoencephalitis in a COVID-19 patient-a case report with literature review. Neuroradiology 63 : 653-661, 2021.
 
P.81 掲載の参考文献
1) Soldatos T, et al : High-resolution 3-T MR neurography of the lumbosacral plexus. Radiographics 33 : 967-987, 2013.
 
2) Chhabra A, et al : High-resolution 3T MR neurography of the brachial plexus and its branches, with emphasis on 3D imaging. AJNR Am J Neuroradiol 34 : 486-497, 2013.
PubMed
3) Hiwatashi A, et al : Evaluation of chronic inflammatory demyelinating polyneuropathy : 3D nervesheath signal increased with inked rest-tissue rapid acquisition of relaxation enhancement imaging (3D SHINKEI). Eur Radiol 27 : 447-453, 2017.
PubMed
4) Hiwatashi A, et al : Lumbar plexus in patients with chronic inflammatory demyelinating polyneuropathy : Evaluation with 3D nerve-sheath signal increased with inked rest-tissue rapid acquisition of relaxation enhancement imaging (3D SHINKEI). Eur J Radiol 93 : 95-99, 2017.
PubMed
5) Hiwatashi A, et al : Simultaneous MR neurography and apparent T2 mapping in brachial plexus : Evaluation of patients with chronic inflammatory demyelinating polyradiculoneuropathy. Magn Reson Imaging 55 : 112-117, 2019.
PubMed
6) Hiwatashi A, et al : Lumbar plexus in patients with chronic inflammatory demyelinating polyradiculoneuropathy : evaluation with simultaneous T2 mapping and neurography method with SHINKEI. Br J Radiol 91 : 20180501, 2018.
PubMed
7) Yamashita T, et al : Whole-body magnetic resonance neurography. N Engl J Med 361 : 538-539, 2009.
PubMed
8) Kakuda T, et al : Diffusion tensor imaging of peripheral nerve in patients with chronic inflammatory demyelinating polyradiculoneuropathy : a feasibility study. Neuroradiology 53 : 955-960, 2011.
PubMed
9) Adachi Y, et al : Brachial and lumbar plexuses in chronic inflammatory demyelinating polyradiculoneuropathy : MRI assessment including apparent diffusion coefficient. Neuroradiology 53 : 3-11, 2011.
PubMed
P.89 掲載の参考文献
1) Thompson AJ, et al : Diagnosis of multiple sclerosis : 2017 revisions of the McDonald criteria. Lancet Neurol 17 : 162-173, 2018.
PubMed
2) Huda S, et al : Neuromyelitis optica spectrum disorders. Clin Med (Lond) 19 : 169-176, 2019.
 
3) Kira J-I : Anti-Neurofascin 155 Antibody-Positive Chronic Inflammatory Demyelinating Polyneuropathy/Combined Central and Peripheral Demyelination : Strategies for Diagnosis and Treatment Based on the Disease Mechanism. Front Neurol 12 : 665136, 2021. (DOI : 10.3389/fneur.2021.665136)
 
4) 多発性硬化症・視神経脊髄炎診療ガイドライン 2017 (日本神経学会監, 「多発性硬化症・視神経脊髄炎診療ガイドライン」作成委員会編), 医学書院, 2017.
 
5) Gronseth GS, Ashman EJ : Practice parameter : the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review) : Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54 : 1720-1725, 2000.
 
6) 飛松省三 : ベッドサイドの臨床神経生理学, 中外医学社, 2017.
 
7) 飛松省三 : ここに気をつける! 誘発電位ナビはじめの一歩から臨床と研究のヒントまで, 南山堂, 2017.
 
8) Leocani L, et al : Multimodal evoked potentials to assess the evolution of multiple sclerosis : a longitudinal study. J Neurol Neurosurg Psychiatry 77 : 1030-1035, 2006.
PubMed
9) 黒川智美, ほか : 電気生理学的診断法. 日本臨牀 61 : 1347-1354, 2003.
Medical*Online
10) 萩原綱一, ほか : 多発性硬化症の電気生理診断学. 多発性硬化症の診断と治療 (吉良潤一編), p66-72, 新興医学出版社, 2008.
 
11) 飛松省三 : 誘発電位の利用の仕方. 診断のコツとピットフォール. MS Frontier 3 : 47-50, 2014.
 
12) Kira J, et al : Primary progressive versus relapsing remitting multiple sclerosis in Japanese patients : a combined clinical, magnetic resonance imaging and multimodality evoked potential study. J Neurol Sci 117 : 179-185, 1993.
PubMed
13) Watanabe A, et al : Multimodality-evoked potential study of anti-aquaporin-4 antibody-positive and-negative multiple sclerosis patients. J Neurol Sci 281 : 34-40, 2009.
PubMed
14) Ogata H, et al : Optic, trigeminal, and facial neuropathy related to anti-neurofascin 155 antibody. Ann Clin Transl Neurol 7 : 2297-2309, 2020.
PubMed
P.96 掲載の参考文献
1) 桑原聡, ほか : ギラン・バレー症候群の電気診断. 臨床神経生理学 33 : 35-44, 2005.
Medical*Online
2) Olsson Y : Microenvironment of the peripheral nervous system under normal and pathological conditions. Crit Rev Neurobiol 5 : 265-311, 1990.
PubMed
3) Kuwabara S, et al : Sensory nerve conduction in demyelinating and axonal Guillain-Barre syndromes. Eur Neurol 51 : 196-198, 2004.
PubMed
4) Brown WF, Snow R : Patterns and severity of conduction abnormalities in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 54 : 768-774, 1991.
PubMed
5) Tamura N, et al : Superficial radial sensory nerve potentials in immune-mediated and diabetic neuropathies. Clin Neurophysiol 116 : 2330-2333, 2005.
PubMed
6) Hiraga A, et al : Recovery patterns and long term prognosis for axonal Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 76 : 719-722, 2005.
PubMed
7) Bromberg MB, Albers JW : Patterns of sensory nerve conduction abnormalities in demyelinating and axonal peripheral nerve disorders. Muscle Nerve 16 : 262-266, 1993.
PubMed
8) Kuwabara S : The blood-nerve barrier and sensory nerve conduction. Clin Neurophysiol 118 : 1901-1902, 2007.
PubMed
9) Kuwabara S, et al : Different electrophysiological profiles and treatment response in 'typical' and 'atypical' chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 86 : 1054-1059, 2015.
PubMed
P.103 掲載の参考文献
1) Yamamoto D, et al : Effect of local cooling on excitation-contraction coupling in myasthenic muscle : Another mechanism of ice-pack test in myasthenia gravis. Clin Neurophysiol 128 : 2309-2317, 2017.
PubMed
2) Park JY, et al : Diagnostic value of repeated ice tests in the evaluation of ptosis in myasthenia gravis. PLoS One 12 : e0177078, 2017.
PubMed
3) Fakiri MO, et al : Accuracy of the ice test in the diagnosis of myasthenia gravis in patients with ptosis. Muscle Nerve 48 : 902-904, 2013.
 
4) Marinos E, et al : Evaluating the temperature effects of ice and heat tests on ptosis due to Myasthenia Gravis. Eye (Lond) 32 : 1387-1391, 2018.
PubMed
5) Sanders DB, et al : Is the decremental pattern in Lambert-Eaton syndrome different from that in myasthenia gravis? Clin Neurophysiol 125 : 1274-1277, 2014.
PubMed
6) Maddison P, et al : Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 65 : 213-217, 1998.
PubMed
7) Ogawa G, et al : A new maneuver for repetitive nerve stimulation testing in the trapezius muscle. Muscle Nerve 47 : 668-672, 2013.
PubMed
8) Abraham A, et al : Repetitive nerve stimulation cutoff values for the diagnosis of myasthenia gravis. Muscle Nerve 55 : 166-170, 2017.
 
9) Rubin DI, Hentschel K : Is exercise necessary with repetitive nerve stimulation in evaluating patients with suspected myasthenia gravis? Muscle Nerve 35 : 103-106, 2007.
PubMed
10) Hatanaka Y, Oh SJ : Ten-second exercise is superior to 30-second exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome. Muscle Nerve 37 : 572-575, 2008.
PubMed
11) Titulaer MJ, et al : Lambert-Eaton myasthenic syndrome : from clinical characteristics to therapeutic strategies. Lancet Neurol 10 : 1098-1107, 2011.
PubMed
12) Chiou-Tan FY, Gilchrist JM : Repetitive nerve stimulation and single-fiber electromyography in the evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome : Review of recent literature. Muscle Nerve 52 : 455-462, 2015.
PubMed
13) Kokubun N, et al : Reference values for voluntary and stimulated single-fibre EMG using concentric needle electrodes : a multicentre prospective study. Clin Neurophysiol 123 : 613-620, 2012.
PubMed
14) Padua L, et al : Reliability of SFEMG in diagnosing myasthenia gravis : sensitivity and specificity calculated on 100 prospective cases. Clin Neurophysiol 125 : 1270-1273, 2014.
PubMed
15) 今井富裕, 幸原伸夫 : 同芯針電極を用いた針筋電図検査. モノグラフ神経筋電気診断を基礎から学ぶ人のために (日本臨床神経生理学会 筋・末梢神経電気診断技術向上委員会, 認定委員会編), p67-73, 日本臨床神経生理学会, 2013.
 
P.109 掲載の参考文献
1) Bjornevik K, et al : Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis. JAMA Neurol 77 : 58-64, 2020.
PubMed
2) Delcoigne B, et al : Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology 94 : e1201-e1212, 2020.
PubMed
3) Bridel C, et al : Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis. Neurology 97 : e1898-e1905, 2021.
PubMed
4) Abdelhak A, et al : Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep 8 : 14798, 2018.
PubMed
5) Watanabe M, et al : Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology 93 : e1299-e1311, 2019.
PubMed
6) Pietrasik S, et al : Circulating miRNAs as Potential Biomarkers Distinguishing Relapsing-Remitting from Secondary Progressive Multiple Sclerosis. A Review. Int J Mol Sci 22 : 11887, 2021.
PubMed
7) Agah E, et al : Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis : A systematic review and meta-analysis. PLoS One 13 : e0190252, 2018.
PubMed
8) van Lierop ZY, et al : Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis. Mult Scler 28 : 102-110, 2022.
PubMed
9) Calabresi PA, et al : The incidence and significance of anti-natalizumab antibodies : results from AFFIRM and SENTINEL. Neurology 69 : 1391-1403, 2007.
PubMed
10) Ellrichmann G, et al : Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. J Neurol 266 : 57-67, 2019.
PubMed
11) Cohen M, et al : Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab : Results from a bicentric study. J Neurol Sci 373 : 335-338, 2017.
PubMed
12) Trewin BP, et al : Precision therapy for neuromyelitis optica spectrum disorder : A retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules. Mult Scler Relat Disord 43 : 102175, 2020.
 
13) Kimura K, et al : Th1-CD11c+ B Cell Axis Associated with Response to Plasmapheresis in Multiple Sclerosis. Ann Neurol 90 : 595-611, 2021.
PubMed
14) Dunn N, et al : Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis. Front Immunol 11 : 583560, 2020.
 
15) Nakatsuji Y, et al : Elevation of Sema4A implicates Th cell skewing and the efficacy of IFN-β therapy in multiple sclerosis. J Immunol 188 : 4858-4865, 2012.
 
P.115 掲載の参考文献
1) Wright BL, et al : Cerebrospinal fluid and lumbar puncture : a practical review. J Neurol 259 : 1530-1545, 2012.
PubMed
2) Jurynczyk M, et al : Overlapping CNS inflammatory diseases : differentiating features of NMO and MS. J Neurol Neurosurg Psychiatry 86 : 20-25, 2015.
 
3) Gross CC, et al : Classification of neurological diseases using multi-dimensional CSF analysis. Brain 144 : 2625-2634, 2021.
PubMed
4) Breiner A, et al : Adult CSF total protein upper reference limits should be age-partitioned and significantly higher than 0.45 g/L : a systematic review. J Neurol 266 : 616-624, 2019.
 
5) Solomon AJ, et al : Misdiagnosis of multiple sclerosis : Impact of the 2017 McDonald criteria on clinical practice. Neurology 92 : 26-33, 2019.
PubMed
6) Petzold A : Intrathecal oligoclonal IgG synthesis in multiple sclerosis. J Neuroimmunol 262 : 1-10, 2013.
PubMed
7) Magliozzi R, Cross AH : Can CSF biomarkers predict future MS disease activity and severity? Mult Scler 26 : 582-590, 2020.
PubMed
8) Matute-Blanch C, et al : Multiple sclerosis, and other demyelinating and autoimmune inflammatory diseases of the central nervous system. In : Handbook of Clinical Neurology ; Cerebrospinal Fluid in Neurologic Disorders (ed by Deisenhammer F, et al), p67-84, Elsevier BV, Amsterdam, 2017.
 
9) Kothur K, et al : CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders : A systematic review. Cytokine 77 : 227-237, 2016.
PubMed
10) Kaneko K, et al : CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS : a cross-sectional study and potential therapeutic implications. J Neurol Neurosurg Psychiatry 89 : 927-936, 2018.
 
11) Hirohata S, et al : Clinical characteristics of neuro-Behcet's disease in Japan : a multicenter retrospective analysis. Mod Rheumatol 22 : 405-413, 2012.
PubMed
12) DiSano KD, et al : Intrathecally produced CXCL13 : A predictive biomarker in multiple sclerosis. Mult Scler J Exp Transl Clin 6 : 2055217320981396, 2020.
PubMed
13) Costerus JM, et al : Technological advances and changing indications for lumbar puncture in neurological disorders. Lancet Neurol 17 : 268-278, 2018.
PubMed
14) Gaetani L, et al : CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases : Implications for Treatment. Trends Pharmacol Sci 41 : 1023-1037, 2020.
PubMed
15) Tobin WO, Pittock SJ : Autoimmune Neurology of the Central Nervous System. Continuum (Minneap Minn) 23 : 627-653, 2017.
PubMed
P.120 掲載の参考文献
1) Waters PJ, et al : Serologic diagnosis of NMO : a multicenter comparison of aquaporin-4-IgG assays. Neurology 78 : 665-671 ; discussion 669, 2012.
 
2) Lindstrom J, Einarson B : Antigenic modulation and receptor loss in experimental autoimmune myasthenia gravis. Muscle Nerve 2 : 173-179, 1979.
PubMed
3) Gambino CM, et al : Comparative Analysis of BIOCHIP Mosaic-Based Indirect Immunofluorescence with Enzyme-Linked Immunosorbent Assay for Diagnosing Myasthenia Gravis. Diagnostics (Basel) 11 : 2098, 2021.
PubMed
4) Higuchi O, et al : Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69 : 418-422, 2011.
PubMed
5) Nakane S, et al : Clinical features of autoimmune autonomic ganglionopathy and the detection of subunit-specific autoantibodies to the ganglionic acetylcholine receptor in Japanese patients. PLoS One 10 : e0118312, 2015.
 
6) Bodle CR, et al : Development of a bimolecular luminescence complementation assay for RGS : G protein interactions in cells. Anal Biochem 522 : 10-17, 2017.
PubMed
7) Eglen RM, et al : The use of AlphaScreen technology in HTS : current status. Curr Chem Genomics 1 : 2-10, 2008.
 
8) Hwang J, et al : Quantitation of low abundant soluble biomarkers using high sensitivity Single Molecule Counting technology. Methods 158 : 69-76, 2019.
PubMed
9) Tzartos SJ, Changeux JP : High affinity binding of alpha-bungarotoxin to the purified alpha-subunit and to its 27,000-dalton proteolytic peptide from Torpedo marmorata acetylcholine receptor. Requirement for sodium dodecyl sulfate. EMBO J 2 : 381-387, 1983.
 
10) Noridomi K, et al : Structural insights into the molecular mechanisms of myasthenia gravis and their therapeutic implications. Elife 6 : e23043, 2017.
PubMed
11) Lennon VA, et al : Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis. J Immunol 146 : 2245-2248, 1991.
PubMed
12) Lazaridis K, et al : Characterization of a reproducible rat EAMG model induced with various human acetylcholine receptor domains. J Neuroimmunol 303 : 13-21, 2017.
PubMed
P.127 掲載の参考文献
1) Collins MP, et al : Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy : executive summary. J Peripher Nerv Syst 15 : 176-184, 2010.
 
2) Ikeda S, et al : Clinicopathological characteristics of subtypes of chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 90 : 988-996, 2019.
PubMed
3) Tracy JA, et al : Onion-bulb patterns predict acquired or inherited demyelinating polyneuropathy. Muscle Nerve 59 : 665-670, 2019.
PubMed
4) Oka N, et al : Two subtypes of Churg-Strauss syndrome with neuropathy : the roles of eosinophils and ANCA. Mod Rheumatol 21 : 290-295, 2011.
PubMed
5) Nishi R, et al : Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA. Neurology 94 : e1726-e1737, 2020.
PubMed
6) Hafer-Macko CE, et al : Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 39 : 625-635, 1996.
PubMed
7) Yan WX, et al : P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50 : 286-292, 2001.
PubMed
8) Oka N, et al : Different profiles of onion bulb in CIDP and CMT1A in relation to extracellular matrix. Clin Neuropathol 32 : 406-412, 2013.
PubMed
9) Gaspar BL, et al : Inflammatory Myopathies. In : Myopathology : A Practical Clinico-pathological Approach to Skeletal Muscle Biopsies, p154-157, Springer, Singapore, 2019.
 
10) Isenberg DA, et al : Localization of interferons and interleukin 2 in polymyositis and muscular dystrophy. Clin Exp Immunol 63 : 450-458, 1986.
PubMed
11) Uruha A, et al : Sarcoplasmic MxA expression : A valuable marker of dermatomyositis. Neurology 88 : 493-500, 2017.
PubMed
12) Aouizerate J, et al : Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy. Acta Neuropathol Commun 2 : 154, 2014.
PubMed

II 中枢神経脱髄疾患

P.137 掲載の参考文献
1) Lassmann H, et al : Immunopathology of multiple sclerosis : report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol 86 : 213-217, 1998.
 
2) Lucchinetti C : Multiple sclerosis pathology during early and late disease phases : pathogenic and clinical relevance. In : Immune Regulation and Immunotherapy in Autoimmune Disease (ed by Zhang J), p2141-2264, Springer, New York, 2007.
 
3) Prineas JW, et al : Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 50 : 646-657, 2001.
PubMed
4) Kutzelnigg A, et al : Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128 : 2705-2712, 2005.
PubMed
5) Frischer JM, et al : Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol 78 : 710-721, 2015.
PubMed
6) Lassmann H, et al : Progressive multiple sclerosis : pathology and pathogenesis. Nat Rev Neurol 8 : 647-656, 2012.
PubMed
7) Hametner S, et al : Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol 74 : 848-861, 2013.
 
8) Vercellino M, et al : Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex : correlation with microglia infiltration, demyelination, and neuronal and synaptic damage. J Neuropathol Exp Neurol 66 : 732-739, 2007.
PubMed
9) Lucchinetti CF, et al : Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 365 : 2188-2197, 2011.
PubMed
10) Serafini B, et al : Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14 : 164-174, 2004.
PubMed
11) Magliozzi R, et al : Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130 : 1089-1104, 2007.
PubMed
12) Howell OW, et al : Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 134 : 2755-2771, 2011.
PubMed
13) Reali C, et al : B cell rich meningeal inflammation associates with increased spinal cord pathology in multiple sclerosis. Brain Pathol 30 : 779-793, 2020.
PubMed
14) Trapp BD, et al : Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis : a retrospective study. Lancet Neurol 17 : 870-884, 2018.
PubMed
15) Matsuoka T, et al : Aquaporin-4 astrocytopathy in Balo's disease. Acta Neuropathol 120 : 651-660, 2010.
PubMed
16) Matsuoka T, et al : Reappraisal of aquaporin-4 astrocytopathy in Asian neuromyelitis optica and multiple sclerosis patients. Brain Pathol 21 : 516-532, 2011.
PubMed
17) Masaki K, et al : Connexin 43 astrocytopathy linked to rapidly progressive multiple sclerosis and neuromyelitis optica. PLoS One 8 : e72919, 2013.
PubMed
18) Masaki K : Early disruption of glial communication via connexin gap junction in multiple sclerosis, Balo's disease and neuromyelitis optica. Neuropathology 35 : 469-480, 2015.
 
19) Bar-Or A, et al : Epstein-Barr Virus in Multiple Sclerosis : Theory and Emerging Immunotherapies. Trends Mol Med 26 : 296-310, 2020.
 
20) Serafini B, et al : Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 204 : 2899-2912, 2007.
 
21) Lanz TV, et al : Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GlialCAM. Nature 603 : 321-327, 2022.
PubMed
P.142 掲載の参考文献
1) Reich DS, et al : Multiple Sclerosis. N Engl J Med 378 : 169-180, 2018.
PubMed
2) Walton C, et al : Rising prevalence of multiple sclerosis worldwide : Insights from the Atlas of MS, third edition. Mult Scler 26 : 1816-1821, 2020.
PubMed
3) Isobe N, et al : Continued increase of multiple sclerosis and neuromyelitis optica and the North-South gradient in Japan ; updates from the 5th nationwide survey. Multiple Sclerosis Journal 26 (3 Suppl) : 334-335, 2020.
 
4) Lublin FD, Reingold SC : Defining the clinical course of multiple sclerosis : results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46 : 907-911, 1996.
PubMed
5) Lublin FD, et al : Defining the clinical course of multiple sclerosis : the 2013 revisions. Neurology 83 : 278-286, 2014.
PubMed
6) Thompson AJ, et al : Diagnosis of multiple sclerosis : 2017 revisions of the McDonald criteria. Lancet Neurol 17 : 162-173, 2018.
PubMed
7) Scalfari A, et al : Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry 85 : 67-75, 2014.
PubMed
8) Confavreux C, Vukusic S : The clinical course of multiple sclerosis. Handb Clin Neurol 122 : 343-369, 2014.
PubMed
9) Miller DH, Leary SM : Primary-progressive multiple sclerosis. Lancet Neurol 6 : 903-912, 2007.
PubMed
10) Brown JWL, et al : Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA 321 : 175-187, 2019.
PubMed
11) Hauser SL, Cree BAC : Treatment of Multiple Sclerosis : A Review. Am J Med 133 : 1380-1390.e2, 2020.
 
12) Inojosa H, et al : A focus on secondary progressive multiple sclerosis (SPMS) : challenges in diagnosis and definition. J Neurol 268 : 1210-1221, 2021.
PubMed
13) Lorscheider J, et al : Defining secondary progressive multiple sclerosis. Brain 139 : 2395-2405, 2016.
PubMed
14) Freedman MS : Induction vs. escalation of therapy for relapsing Multiple Sclerosis : The evidence. Neurol Sci 29 (Suppl 2) : S250-252, 2008.
 
15) Rush CA, et al : Aggressive multiple sclerosis : proposed definition and treatment algorithm. Nat Rev Neurol 11 : 379-389, 2015.
PubMed
P.148 掲載の参考文献
1) Thompson AJ, et al : Diagnosis of multiple sclerosis : 2017 revisions of the McDonald criteria. Lancet Neurol 17 : 162-173, 2018.
PubMed
2) Okuda DT, et al : Radiologically isolated syndrome : 5-year risk for an initial clinical event. PLoS One 9 : e90509, 2014.
PubMed
3) Filippi M, et al : MRI criteria for the diagnosis of multiple sclerosis : MAGNIMS consensus guidelines. Lancet Neurol 15 : 292-303, 2016.
 
4) Thaler C, et al : T1 Recovery Is Predominantly Found in Black Holes and Is Associated with Clinical Improvement in Patients with Multiple Sclerosis. AJNR Am J Neuroradiol 38 : 264-269, 2017.
PubMed
5) Sati P, et al : The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis : a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol 12 : 714-722, 2016.
 
6) Rotstein D, Montalban X : Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol 15 : 287-300, 2019.
PubMed
7) Brownlee WJ, et al : Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain 142 : 2276-2287, 2019.
PubMed
8) Absinta M, et al : Identification of Chronic Active Multiple Sclerosis Lesions on 3T MRI. AJNR Am J Neuroradiol 39 : 1233-1238, 2018.
PubMed
9) Saidha S, et al : Optical coherence tomography reflects brain atrophy in multiple sclerosis : A four-year study. Ann Neurol 78 : 801-813, 2015.
PubMed
10) Martinez-Lapiscina EH, et al : Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis : a cohort study. Lancet Neurol 15 : 574-584, 2016.
PubMed
11) Martinez MA, et al : Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler 21 : 550-561, 2015.
PubMed
12) Disanto G, et al : Serum Neurofilament light : A biomarker of neuronal damage in multiple sclerosis. Ann Neurol 81 : 857-870, 2017.
 
13) Barro C, et al : Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 141 : 2382-2391, 2018.
PubMed
14) Takahashi K, et al : Association of cerebrospinal fluid levels of lateral olfactory tract usher substance (LOTUS) with disease activity in multiple sclerosis. JAMA Neurol 72 : 176-179, 2015.
PubMed
15) Magliozzi R, et al : Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. Ann Neurol 83 : 739-755, 2018.
PubMed
16) Marastoni D, et al : CSF Levels of CXCL12 and Osteopontin as Early Markers of Primary Progressive Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm 8 : e1083, 2021.
PubMed
P.152 掲載の参考文献
1) Kurtzke JF : Rating neurologic impairment in multiple sclerosis : an expanded disability status scale (EDSS). Neurology 33 : 1444-1452, 1983.
PubMed
2) Cutter GR, et al : Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122 (Pt 5) : 871-882, 1999.
 
3) Rudick RA, et al : Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler 15 : 984-997, 2009.
PubMed
4) Miller DM, et al : Clinical significance of the multiple sclerosis functional composite : relationship to patient-reported quality of life. Arch Neurol 57 : 1319-1324, 2000.
PubMed
5) Sumowski JF, et al : Cognition in multiple sclerosis : State of the field and priorities for the future. Neurology 90 : 278-288, 2018.
PubMed
6) Drake AS, et al : Psychometrics and normative data for the Multiple Sclerosis Functional Composite : replacing the PASAT with the Symbol Digit Modalities Test. Mult Scler 16 : 228-237, 2010.
PubMed
7) Benedict RH, Zivadinov R : Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol 7 : 332-342, 2011.
PubMed
8) Niino M, et al : Apathy/depression, but not subjective fatigue, is related with cognitive dysfunction in patients with multiple sclerosis. BMC Neurol 14 : 3, 2014.
PubMed
9) Niino M, et al : Validation of the Brief International Cognitive Assessment for Multiple Sclerosis in Japan. Mult Scler J Exp Transl Clin 3 : 2055217317748972, 2017.
PubMed
10) Niino M, Miyazaki Y : Cognitive impairment as one of the important non-motor symptoms in multiple sclerosis and neuromyelitis optica spectrum disorders. Clin Exp Neuroimmunol 10 : 152-160, 2019.
 
11) Rao SM, et al : Processing speed test : Validation of a self-administered, iPad-based tool for screening cognitive dysfunction in a clinic setting. Mult Scler 23 : 1929-1937, 2017.
 
12) Niino M, et al : Developing standard data of cognitive function using processing speed test in Japanese healthy volunteers and comparison to the US normative data. The 8th Joint ACTRIMS-ECTRIMS meeting. Web, September 9-12, 2020.
 
13) Litster B, et al : Screening Tools for Anxiety in People with Multiple Sclerosis : A Systematic Review. Int J MS Care 18 : 273-281, 2016.
PubMed
14) Niino M, et al : Correlation of the Symbol Digit Modalities Test with the Quality of Life and Depression in Japanese patients with Multiple Sclerosis. Mult Scler Relat Disord 57 : 103427, 2022.
PubMed
15) Rudick RA, et al : Health-related quality of life in multiple sclerosis : effects of natalizumab. Ann Neurol 62 : 335-346, 2007.
PubMed
16) Kikuchi H, et al : Impact and characteristics of quality of life in Japanese patients with multiple sclerosis. Qual Life Res 20 : 119-131, 2011.
PubMed
17) Wynia K, et al : The impact of disabilities on quality of life in people with multiple sclerosis. Mult Scler 14 : 972-980, 2008.
PubMed
P.160 掲載の参考文献
1) 多発性硬化症・視神経脊髄炎診療ガイドライン 2017 (「多発性硬化症・視神経脊髄炎診療ガイドライン」作成委員会編, 日本神経学会監), 医学書院, 2017.
 
2) University of California, San Francisco MS-EPIC Team ; Cree BAC, et al : Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol 80 : 499-510, 2016.
 
3) Coret F, et al : Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies. Mult Scler J Exp Transl Clin 4 : 2055217318783347, 2018.
PubMed
4) Tremlett H, et al : Natural history of secondary-progressive multiple sclerosis. Mult Scler 14 : 314-324, 2008.
PubMed
5) Brown JWL, et al : Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA 321 : 175-187, 2019.
PubMed
6) He A, et al : Timing of high-efficacy therapy for multiple sclerosis : a retrospective observational cohort study. Lancet Neurol 19 : 307-316, 2020.
 
7) Rotstein D, Montalban X : Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol 15 : 287-300, 2019.
PubMed
8) Vukusic S, Confavreux C : Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci 206 : 135-137, 2003.
PubMed
9) Malpas CB, et al : Early clinical markers of aggressive multiple sclerosis. Brain 143 : 1400-1413, 2020.
PubMed
10) Lebrun-Frenay C, et al : Radiologically Isolated Syndrome : 10-Year Risk Estimate of a Clinical Event. Ann Neurol 88 : 407-417, 2020.
PubMed
11) Brownlee WJ, et al : Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain 142 : 2276-2287, 2019.
PubMed
12) Chung KK, et al : A 30-Year Clinical and Magnetic Resonance Imaging Observational Study of Multiple Sclerosis and Clinically Isolated Syndromes. Ann Neurol 87 : 63-74, 2020.
PubMed
13) Tintore M, et al : Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. Neurology 97 : e1641-e1652, 2021.
PubMed
14) Kalincik T, et al : Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology 96 : e783-e797, 2021.
 
15) Spelman T, et al : Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis : Data From 2 Different National Strategies. JAMA Neurol 78 : 1197-1204, 2021.
PubMed
16) Kappos L, et al : Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND) : a double-blind, randomised, phase 3 study. Lancet 391 : 1263-1273, 2018.
PubMed
17) Hauser SL, et al : Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med 383 : 546-557, 2020.
PubMed
P.166 掲載の参考文献
1) Li R, et al : Reassessing B cell contributions in multiple sclerosis. Nat Immunol 19 : 696-707, 2018.
 
2) Bar-Or A, Li R : Cellular immunology of relapsing multiple sclerosis : interactions, checks, and balances. Lancet Neurol 20 : 470-483, 2021.
 
3) Comi G, et al : Role of B Cells in Multiple Sclerosis and Related Disorders. Ann Neurol 89 : 13-23, 2021.
 
4) Shinoda K, et al : Cellular immune profiling pre- and post-aCD20 therapy points to differential effects on CD4+ and CD8+ T cells and implicates CD20-expressing CD8+ T cells in MS disease activity. Presented at ECTRIMS 189, 2021.
 
5) Bar-Or A, et al : Rituximab in relapsing-remitting multiple sclerosis : a 72-week, open-label, phase I trial. Ann Neurol 63 : 395-400, 2008.
 
6) Hauser SL, et al : B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358 : 676-688, 2008.
PubMed
7) Kappos L, et al : Ocrelizumab in relapsing-remitting multiple sclerosis : a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378 : 1779-1787, 2011.
PubMed
8) Hauser SL, et al : Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 376 : 221-234, 2017.
PubMed
9) Hauser SL, et al : Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med 383 : 546-557, 2020.
PubMed
10) Kira JI, et al : Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia : Phase 2 APOLITOS study. Mult Scler, 2021. (DOI : 10.1177/13524585211055934)
 
11) Bar-Or A, et al : Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis : APLIOS, a randomized phase-2 study. Mult Scler, 2021. (DOI : 10.1177/13524585211044479)
 
12) Hawker K, et al : Rituximab in patients with primary progressive multiple sclerosis : results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66 : 460-471, 2009.
PubMed
13) Montalban X, et al : Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 376 : 209-220, 2017.
PubMed
14) Wolinsky JS, et al : Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial : 6.5-study year follow-up data. Presented at ECTRIMS 159, 2019.
 
15) de Seze J, et al : Effect of ofatumumab on serum immunoglobulin levels and infection risk in relapsing multiple sclerosis patients from the phase 3 ASCLEPIOS I and II trials. Presented at the 6th Congress of the European Academy of Neurology ; LB82.
 
16) Cross AH, et al : Outcomes of COVID-19 in patients with relapsing multiple sclerosis receiving ofatumumab : Data from the ALITHIOS study and post marketing surveillance. Presented at ECTRIMS p982, 2021.
 
17) Sormani MP, et al : Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol 89 : 780-789, 2021.
PubMed
18) National Multiple Sclerosis Society : COVID-19 Vaccine Guidance for People Living with MS, updated on December 17, 2021. [https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance]
 
P.171 掲載の参考文献
1) Bogosian A, et al : Multiple challenges for people after transitioning to secondary progressive multiple sclerosis : a qualitative study. BMJ Open 9 : e026421, 2019.
PubMed
2) Manouchehrinia A, et al : Predicting risk of secondary progression in multiple sclerosis : A nomogram. Mult Scler 25 : 1102-1112, 2019.
PubMed
3) Houzen H, et al : Consistent increase in the prevalence and female ratio of multiple sclerosis over 15 years in northern Japan. Eur J Neurol 25 : 334-339, 2018.
PubMed
4) Iaffaldano P, et al : Transition to secondary progression in relapsing-onset multiple sclerosis : Definitions and risk factors. Mult Scler 27 : 430-438, 2021.
PubMed
5) Lublin FD, et al : Defining the clinical course of multiple sclerosis : the 2013 revisions. Neurology 83 : 278-286, 2014.
PubMed
6) Kappos L, et al : Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Mult Scler 24 : 963-973, 2018.
 
7) University of California, San Francisco MS-EPIC Team ; Cree BAC, et al : Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol 85 : 653-666, 2019.
PubMed
8) Larochelle C, et al : Secondary Progression in Multiple Sclerosis : Neuronal Exhaustion or Distinct Pathology? Trends Neurosci 39 : 325-339, 2016.
PubMed
9) Kappos L, et al : Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND) : a double-blind, randomised, phase 3 study. Lancet 391 : 1263-1273, 2018.
PubMed
10) Benedict RHB, et al : Siponimod and Cognition in Secondary Progressive Multiple Sclerosis : EXPAND Secondary Analyses. Neurology 96 : e376-e386, 2021.
PubMed
11) Hauser SL, et al : Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med 383 : 546-557, 2020.
PubMed
12) Cadavid D, et al : The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler 23 : 94-105, 2017.
PubMed
13) Eshaghi A, et al : Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol 83 : 210-222, 2018.
PubMed
14) Colato E, et al : Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes. J Neurol Neurosurg Psychiatry 92 : 995-1006, 2021.
PubMed
15) Absinta M, et al : Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology 85 : 18-28, 2015.
PubMed
16) Makshakov G, et al : Leptomeningeal Contrast Enhancement Is Associated with Disability Progression and Grey Matter Atrophy in Multiple Sclerosis. Neurol Res Int 2017 : 8652463, 2017.
PubMed
17) Barro C, et al : Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 141 : 2382-2391, 2018.
PubMed
18) Bhan A, et al : Neurofilaments and 10-year follow-up in multiple sclerosis. Mult Scler 24 : 1301-1307, 2018.
PubMed
19) Abdelhak A, et al : Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep 8 : 14798, 2018.
PubMed
20) Bsteh G, et al : Peripapillary retinal nerve fibre layer thinning rate as a biomarker discriminating stable and progressing relapsing-remitting multiple sclerosis. Eur J Neurol 26 : 865-871, 2019.
PubMed
21) Bsteh G, et al : Macular ganglion cell-inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis. Mult Scler 27 : 684-694, 2021.
PubMed
P.177 掲載の参考文献
1) Ontaneda D, et al : Progressive multiple sclerosis : prospects for disease therapy, repair, and restoration of function. Lancet 389 : 1357-1366, 2017.
PubMed
2) 多発性硬化症・視神経脊髄炎診療ガイドライン 2017 (日本神経学会監), p116-117, 医学書院, 2017.
 
3) Miller DH, et al : Primary-progressive multiple sclerosis. Lancet Neurol 6 : 903-912, 2007.
PubMed
4) Confavreux C, et al : Relapses and progression of disability in multiple sclerosis. N Engl J Med 343 : 1430-1438, 2000.
PubMed
5) 医療用医薬品 : メーゼント, 添付文書. [https://pins.japic.or.jp/pdf/newPINS/00068876.pdf]
 
6) Ocrelizumab accessdata.fda.gov. [https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf]
 
7) How does ocrevus work. [https://getonwithlife.co.nz/about-ocrevus/how-does-ocrevus-work/]
 
8) IBM Micromedex. Mayo Clinic. Ocrelizumab (Intravenous Route). [https://www.mayoclinic.org/drugs-supplements/ocrelizumab-intravenous-route/side-effects/drg-20406139?p=1]
 
9) Montalban X, et al : Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 376 : 209-220, 2017.
PubMed
10) Ocrelizumab and PML. [https://www.ocrelizumabinfo.com/content/dam/gene/ocrelizumabinfo/pdfs/progressive-multifocal-leukoencephalopathy.pdf]
 
11) Patel A, et al : Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy. JAMA Neurol 78 : 736-740, 2021.
 
12) Florou D, et al : Anti-CD20 Agents for Multiple Sclerosis : Spotlight on Ocrelizumab and Ofatumumab. Brain Sci 10 : 758, 2020. (DOI : 10.3390/brainsci10100758)
 
13) Dolgin E : BTK blockers make headway in multiple sclerosis. Nat Biotechnol 39 : 3-5, 2021.
PubMed
14) 医療用医薬品 : カルケンス, 添付文書. [https://pins.japic.or.jp/pdf/newPINS/00069234.pdf]
 
15) 多発性硬化症・視神経脊髄炎診療ガイドライン 2017 (日本神経学会監), p286-288, 医学書院, 2017.
 
P.181 掲載の参考文献
1) Jarius S, et al : The first Japanese report on neuromyelitis optica rediscovered : acute bilateral blindness, tetraparesis and respiratory insufficiency in a 35-year-old man (1891). J Neurol Sci 395 : 121-125, 2018.
 
2) Jarius S, Wildemann B : The history of neuromyelitis optica. J Neuroinflammation 10 : 8, 2013.
PubMed
3) Lennon VA, et al : A serum autoantibody marker of neuromyelitis optica : distinction from multiple sclerosis. Lancet 364 : 2106-2112, 2004.
PubMed
4) Lennon VA, et al : IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202 : 473-477, 2005.
 
5) Wingerchuk DM, et al : The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53 : 1107-1114, 1999.
PubMed
6) Lucchinetti CF, et al : A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125 : 1450-1461, 2002.
 
7) Nagelhus EA, et al : Aquaporin-4 in the central nervous system : cellular and subcellular distribution and coexpression with KIR4.1. Neuroscience 129 : 905-913, 2004.
PubMed
8) Saadoun S, et al : Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133 : 349-361, 2010.
PubMed
9) Soltys J, et al : Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica. J Clin Invest 129 : 2000-2013, 2019.
PubMed
10) Zhang H, Verkman AS : Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J Clin Invest 123 : 2306-2316, 2013.
PubMed
11) Hinson SR, et al : Molecular outcomes of neuromyelitis optica (NMO) -IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A 109 : 1245-1250, 2012.
PubMed
12) Guo Y, et al : Spectrum of sublytic astrocytopathy in neuromyelitis optica. Brain, awab394, 2021. (DOI : 10.1093/brain/awab394)
 
13) Chihara N, et al : Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 108 : 3701-3706, 2011.
PubMed
14) Kimura A, Kishimoto T : IL-6 : regulator of Treg/Th17 balance. Eur J Immunol 40 : 1830-1835, 2010.
PubMed
15) Kaplin AI, et al : IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest 115 : 2731-2741, 2005.
PubMed
16) Pittock SJ, et al : Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med 381 : 614-625, 2019.
PubMed
17) Yamamura T, et al : Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med 381 : 2114-2124, 2019.
PubMed
18) Cree BAC, et al : Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum) : a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 394 : 1352-1363, 2019.
PubMed
19) Nishiyama S, et al : A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology 72 : 1960-1961, 2009.
 
20) Roemer SF, et al : Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130 : 1194-1205, 2007.
PubMed
21) Yanagawa K, et al : Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology 73 : 1628-1637, 2009.
PubMed
22) Hokari M, et al : Clinicopathological features in anterior visual pathway in neuromyelitis optica. Ann Neurol 79 : 605-624, 2016.
PubMed
23) Ohara S, et al : Neuromyelitis optica spectrum disorder with massive basal ganglia involvement : a case report. BMC Neurol 19 : 351, 2019.
 
24) Saji E, et al : Cognitive impairment and cortical degeneration in neuromyelitis optica. Ann Neurol 73 : 65-76, 2013.
PubMed
25) Guo Y, et al : Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica. Acta Neuropathol 133 : 597-612, 2017.
PubMed
26) Kappos L, et al : Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol 77 : 1132-1140, 2020.
 
27) Lassmann H : Multiple Sclerosis Pathology. Cold Spring Harb Perspect Med 8 : a028936, 2018.
PubMed
28) Kawachi I, Lassman H : Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry 88 : 137-145, 2017.
 
29) Thompson AJ, et al : Multiple sclerosis. Lancet 391 : 1622-1636, 2018.
PubMed
30) Ransohoff RM, et al : Multiple sclerosis-a quiet revolution. Nat Rev Neurol 11 : 134-142, 2015.
PubMed
31) 河内泉, 西澤正豊 : アクアポリンと視神経脊髄炎. Clinical Neuroscience 33 : 83-87, 2015.
 
P.188 掲載の参考文献
1) Lennon VA, et al : A serum autoantibody marker of neuromyelitis optica : distinction from multiple sclerosis. Lancet 364 : 2106-2112, 2004.
PubMed
2) Wingerchuk DM, et al : International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85 : 177-189, 2015.
PubMed
3) Hor JY, et al : Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol 11 : 501, 2020.
PubMed
4) 高橋利幸, ほか : M23抗原を用いたAQP4Ab ELISA「コスミック」II キットの基礎的・臨床的検討. 医学と薬学 73 : 1297-1300, 2016.
Medical*Online
5) Takano R, et al : Astrocytic damage is far more severe than demyelination in NMO : a clinical CSF biomarker study. Neurology 75 : 208-216, 2010.
PubMed
6) Salama S, Levy M : Bright spotty lesions as an imaging marker for neuromyelitis optica spectrum disorder. Mult Scler 1352458521994259, 2021.
PubMed
7) Kim HJ, et al : MRI characteristics of neuromyelitis optica spectrum disorder : an international update. Neurology 84 : 1165-1173, 2015.
PubMed
8) Oertel FC, et al : Retinal Optical Coherence Tomography in Neuromyelitis Optica. Neurol Neuroimmunol Neuroinflamm 8 : 2021.
PubMed
9) Weinshenker BG, et al : NMO-IgG : a specific biomarker for neuromyelitis optica. Dis Markers 22 : 197-206, 2006.
PubMed
10) Kanamori Y, et al : Pain in neuromyelitis optica and its effect on quality of life : a cross-sectional study. Neurology 77 : 652-658, 2011.
PubMed
11) Ayzenberg I, et al : Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder : A Cross-Sectional Study of 166 AQP4 Antibody-Seropositive Patients. Neurol Neuroimmunol Neuroinflamm 8 : e985, 2021.
PubMed
12) Seok JM, et al : Fatigue in patients with neuromyelitis optica spectrum disorder and its impact on quality of life. PLoS One 12 : e0177230, 2017.
PubMed
13) Saji E, et al : Cognitive impairment and cortical degeneration in neuromyelitis optica. Ann Neurol 73 : 65-76, 2013.
PubMed
14) Liu Y, et al : Structural MRI substrates of cognitive impairment in neuromyelitis optica. Neurology 85 : 1491-1499, 2015.
PubMed
P.195 掲載の参考文献
1) Jarius S, et al : Neuromyelitis optica. Nat Rev Dis Primers 6 : 85, 2020.
PubMed
2) 多発性硬化症・視神経脊髄炎診療ガイドライン 2017 (日本神経学会監, 「多発性硬化症・視神経脊髄炎診療ガイドライン」作成委員会編), 医学書院, 2017.
 
3) Yamasaki R, et al : Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica. Mult Scler 22 : 1337-1348, 2016.
PubMed
4) Watanabe S, et al : Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 13 : 128-132, 2007.
PubMed
5) Fujihara K : Neuromyelitis optica spectrum disorders : still evolving and broadening. Curr Opin Neurol 32 : 385-394, 2019.
PubMed
6) Mimura O, et al : Intravenous immunoglobulin treatment for steroid-resistant optic neuritis : a multicenter, double-blind, randomized, controlled phase III study. Jpn J Ophthalmol 65 : 122-132, 2021.
PubMed
7) Takai Y, et al : Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy. Mult Scler Relat Disord 49 : 102750, 2021.
PubMed
8) Mao-Draayer Y, et al : Neuromyelitis optica spectrum disorders and pregnancy : therapeutic considerations. Nat Rev Neurol 16 : 154-170, 2020.
PubMed
9) Nikoo Z, et al : Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder : a randomized clinical trial. J Neurol 264 : 2003-2009, 2017.
PubMed
10) Costanzi C, et al : Azathioprine : tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77 : 659-666, 2011.
PubMed
11) Torres J, et al : Analysis of the treatment of neuromyelitis optica. J Neurol Sci 351 : 31-35, 2015.
PubMed
12) Huh SY, et al : Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol 71 : 1372-1378, 2014.
PubMed
13) Kojima M, et al : Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody. Mult Scler Relat Disord 39 : 101907, 2019.
PubMed
14) Kageyama T, et al : Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol 260 : 627-634, 2013.
PubMed
15) Zhang C, et al : Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO) : an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol 19 : 391-401, 2020.
 
P.199 掲載の参考文献
1) Fujihara K, et al : Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol 3 : 58-73, 2012.
 
2) Wingerchuk DM, et al : International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85 : 177-189, 2015.
PubMed
3) Kuroda H, Fujihara K : [Current Status and Prospects of Complement-Targeting Therapy for Neuromyelitis Optica]. Brain Nerve 71 : 573-580, 2019.
PubMed
4) Hinson SR, et al : Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 69 : 2221-2231, 2007.
PubMed
5) Chihara N, et al : Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 108 : 3701-3706, 2011.
PubMed
6) Cree BA, et al : An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64 : 1270-1272, 2005.
PubMed
7) Annovazzi P, et al : Rituximab in the treatment of Neuromyelitis optica : a multicentre Italian observational study. J Neurol 263 : 1727-1735, 2016.
PubMed
8) Pittock SJ, et al : Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med 381 : 614-625, 2019.
PubMed
9) Cree BAC, et al : Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum) : a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 394 : 1352-1363, 2019.
PubMed
10) Yamamura T, et al : Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med 381 : 2114-2124, 2019.
PubMed
11) Miyata T, et al : Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 330 : 249-255, 1994.
PubMed
12) Hillmen P, et al : Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 350 : 552-559, 2004.
PubMed
13) Legendre CM, et al : Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368 : 2169-2181, 2013.
PubMed
14) Howard JF, et al : Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN) : a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16 : 976-986, 2017.
PubMed
15) Pittock SJ, et al : Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders : an open-label pilot study. Lancet Neurol 12 : 554-562, 2013.
PubMed
16) Wingerchuk DM, et al : Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. Ann Neurol 89 : 1088-1098, 2021.
PubMed
17) Pittock SJ, et al : Eculizumab monotherapy for NMOSD : Data from PREVENT and its open-label extension. Mult Scler 28 : 480-486, 2022.
PubMed
18) Nishimura J, et al : Genetic variants in C5 and poor response to eculizumab. N Engl J Med 370 : 632-639, 2014.
PubMed
19) McKeage K : Ravulizumab : First Global Approval. Drugs 79 : 347-352, 2019.
PubMed
P.205 掲載の参考文献
1) Wingerchuk DM, et al : International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85 : 177-189, 2015.
PubMed
2) Chihara N, et al : Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 108 : 3701-3706, 2011.
PubMed
3) Araki M, et al : Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica : a pilot study. Neurology 82 : 1302-1306, 2014.
PubMed
4) Yamamura T, et al : Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med 381 : 2114-2124, 2019.
PubMed
5) Traboulsee A, et al : Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder : a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 19 : 402-412, 2020.
 
6) 竹内勤 : RAにおける抗サイトカイン療法. Drug Delivery System 19 : 95-102, 2004.
 
7) Sellner J, et al : Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders : Implications from immunology, the FcRn pathway and clinical experience. Drug Discov Today 26 : 1591-1601, 2021.
PubMed
8) Fujihara K, et al : Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm 7 : e841, 2020.
PubMed
9) エンスプリング皮下注120 mg シリンジ添付文書, 中外製薬株式会社, 2022年1月改訂 (第4版).
 
10) エンスプリング皮下注120 mg シリンジ適正使用ガイド, 中外製薬株式会社.
 
P.210 掲載の参考文献
1) Pittock SJ, et al : Hope for patients with neuromyelitis optica spectrum disorders-from mechanisms to trials. Nat Rev Neurol 17 : 759-773, 2021.
PubMed
2) Nakamura M, et al : An autopsied case of neuromyelitis optica with a large cavitary cerebral lesion. Mult Scler 11 : 735-738, 2005.
PubMed
3) Takeshita Y, et al : Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm 4 : e311, 2017.
PubMed
4) Chihara N, et al : Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 108 : 3701-3706, 2011.
PubMed
5) Kowarik MC, et al : CNS Aquaporin-4-specific B cells connect with multiple B-cell compartments in neuromyelitis optica spectrum disorder. Ann Clin Transl Neurol 4 : 369-380, 2017.
PubMed
6) Nishiyama S, et al : A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology 72 : 1960-1961, 2009.
 
7) Imamura H, et al : [Trial of rituximab in three patients with neuromyelitis optica]. Rinsho Shinkeigaku 49 : 457-462, 2009.
PubMed
8) Tahara M, et al : Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study) : a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 19 : 298-306, 2020.
 
9) Cree BAC, et al : Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum) : a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 394 : 1352-1363, 2019.
PubMed
10) Tahara M, et al : Compassionate open-label use of rituximab following a randomized clinical trial against neuromyelitis optica (RIN-2 study) : B cell monitoring-based administration. Mult Scler Relat Disord 60 : 103730, 2022. (DOI : https://doi.org/10.1016/j.msard.2022.103730)
 
11) Cree BA, et al : Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. Mult Scler 27 : 2052-2061, 2021.
 
12) Rensel M, et al : Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder : Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for > 4 years in the N-MOmentum trial. Mult Scler, 2021. (DOI : 10.1177/13524585211047223)
 
13) Marignier R, et al : Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. Neurol Neuroimmunol Neuroinflamm 8 : e978, 2021.
 
14) Aktas O, et al : Serum Glial Fibrillary Acidic Protein : A Neuromyelitis Optica Spectrum Disorder Biomarker. Ann Neurol 89 : 895-910, 2021.
PubMed
15) Flanagan EP, et al : Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study. Mult Scler Relat Disord 57 : 103352, 2022.
 
16) Louapre C, et al : Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 93 : 24-31, 2022.
 
P.217 掲載の参考文献
1) 藤盛寿一, 中島一郎 : 抗MOG抗体関連疾患. BRAIN and NERVE 73 : 483-488, 2021.
 
2) Johns TG, Bernard CC : The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem 72 : 1-9, 1999.
PubMed
3) Sato DK, et al : Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82 : 474-481, 2014.
PubMed
4) Ramanathan S, et al : Anti-MOG antibody : The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev 15 : 307-324, 2016.
PubMed
5) Kaneko K, et al : CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS : a cross-sectional study and potential therapeutic implications. J Neurol Neurosurg Psychiatry 89 : 927-936, 2018.
 
6) Dos Passos GR, et al : MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis : Lessons Learned From Neuromyelitis Optica Spectrum Disorder. Front Neurol 9 : 217, 2018.
PubMed
7) Akaishi T, et al : Different etiologies and prognoses of optic neuritis in demyelinating diseases. J Neuroimmunol 299 : 152-157, 2016.
PubMed
8) Kitley J, et al : Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies : a comparative study. JAMA Neurol 71 : 276-283, 2014.
PubMed
9) Krupp LB, et al : International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders : revisions to the 2007 definitions. Mult Scler 19 : 1261-1267, 2013.
 
10) Armangue T, et al : Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies : a multicentre observational study. Lancet Neurol 19 : 234-246, 2020.
 
11) Ogawa R, et al : MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm 4 : e322, 2017.
PubMed
12) Budhram A, et al : Unilateral cortical FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES) : characterization of a distinct clinico-radiographic syndrome. J Neurol 266 : 2481-2487, 2019.
PubMed
13) Ikeda T, et al : The pathological features of MOG antibody-positive cerebral cortical encephalitis as a new spectrum associated with MOG antibodies : A case report. J Neurol Sci 392 : 113-115, 2018.
PubMed
14) Titulaer MJ, et al : Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 75 : 411-428, 2014.
PubMed
15) Fujimori J, et al : Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies. J Neurol Neurosurg Psychiatry 88 : 534-536, 2017.
 
16) Banks SA, et al : Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. J Neurol Neurosurg Psychiatry 92 : 384-390, 2021.
 
17) Kunchok A, et al : Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD)? Neurology 94 : 85-88, 2020.
PubMed
18) Jarius S, et al : MOG-IgG in NMO and related disorders : a multicenter study of 50 patients. Part 2 : Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 13 : 280, 2016.
PubMed
19) Ramanathan S, et al : Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 89 : 127-137, 2018.
PubMed
20) Bruijstens AL, et al : E.U. paediatric MOG consortium consensus : Part 1-Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol 29 : 2-13, 2020.
PubMed
21) de Mol CL, et al : The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler 26 : 806-814, 2020.
PubMed
22) Cobo-Calvo A, et al : Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Ann Neurol 89 : 30-41, 2021.
PubMed
23) Lopez-Chiriboga AS, et al : Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder. JAMA Neurol 77 : 1575-1577, 2020.
PubMed
P.224 掲載の参考文献
1) Lucchinetti CF, et al : Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131 : 1759-1775, 2008.
PubMed
2) Altintas A, et al : Clinical and radiological characteristics of tumefactive demyelinating lesions : follow-up study. Mult Scler 18 : 1448-1453, 2012.
PubMed
3) 清水優子 : Tumefactive Demyelinating Disease. MS Frontier 2 : 45-48, 2013.
Medical*Online
4) Kobayashi M, et al : Gadolinium enhancement patterns of tumefactive demyelinating lesions : correlations with brain biopsy findings and pathophysiology. J Neurol 261 : 1902-1910, 2014.
PubMed
5) Masdeu JC, et al : Multiple sclerosis--when and how to image. American College of Radiology. ACR Appropriateness Criteria. Radiology 215 (Suppl) : 547-562, 2000.
PubMed
6) Cha S, et al : Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions. AJNR Am J Neuroradiol 22 : 1109-1116, 2001.
PubMed
7) Given CA, et al : The MRI appearance of tumefactive demyelinating lesions. AJR Am J Roentgenol 182 : 195-199, 2004.
PubMed
8) Schiepers C, et al : Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis. Mult Scler 3 : 8-17, 1997.
PubMed
9) Visser F, et al : Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology 79 : 2000-2003, 2012.
PubMed
10) Pilz G, et al : Tumefactive MS lesions under fingolimod : a case report and literature review. Neurology 81 : 1654-1658, 2013.
PubMed
11) Jander S, et al : Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler 18 : 1650-1652, 2012.
PubMed
12) Lapucci C, et al : Different MRI patterns in MS worsening after stopping fingolimod. Neurol Neuroimmunol Neuroinflamm 6 : e566, 2019.
PubMed
13) Croteau D, et al : Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation. Mult Scler 27 : 903-912, 2021.
PubMed
14) Balo J : Encephalitis periaxialis concentrica. Arch NeurPsych 19 : 242-264, 1928.
 
P.227 掲載の参考文献
1) Stuve O, Zamvil SS : Pathogenesis, diagnosis, and treatment of acute disseminated encephalomyelitis. Curr Opin Neurol 12 : 395-401, 1999.
PubMed
2) Albert LJ, Inman RD : Molecular mimicry and autoimmunity. N Engl J Med 341 : 2068-2074, 1999.
PubMed
3) Jorens PG, et al : Encephalomyelitis-associated antimyelin autoreactivity induced by streptococcal exotoxins. Neurology 54 : 1433-1441, 2000.
PubMed
4) Tenembaum S, et al : Acute disseminated encephalomyelitis. Neurology 68 : S23-36, 2007.
PubMed
5) Paterson RW, et al : The emerging spectrum of COVID-19 neurology : clinical, radiological and laboratory findings. Brain 143 : 3104-3120, 2020.
PubMed
6) Baxter R, et al : Acute Demyelinating Events Following Vaccines : A Case-Centered Analysis. Clin Infect Dis 63 : 1456-1462, 2016.
PubMed
7) Yamaguchi Y, et al : A nationwide survey of pediatric acquired demyelinating syndromes in Japan. Neurology 87 : 2006-2015, 2016.
PubMed
8) Cole J, et al : Acute Disseminated Encephalomyelitis in Children : An Updated Review Based on Current Diagnostic Criteria. Pediatr Neurol 100 : 26-34, 2019.
PubMed
9) Lopez-Chiriboga AS, et al : Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. JAMA Neurol 75 : 1355-1363, 2018.
PubMed
10) Duignan S, et al : Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes. Dev Med Child Neurol 60 : 958-962, 2018.
PubMed
11) Callen DJ, et al : Role of MRI in the differentiation of ADEM from MS in children. Neurology 72 : 968-973, 2009.
PubMed
12) Pavone P, et al : Acute disseminated encephalomyelitis : a long-term prospective study and meta-analysis. Neuropediatrics 41 : 246-255, 2010.
PubMed
13) Krupp LB, et al : International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders : revisions to the 2007 definitions. Mult Scler 19 : 1261-1267, 2013.
 
14) Brenton JN, Banwell BL : Therapeutic Approach to the Management of Pediatric Demyelinating Disease : Multiple Sclerosis and Acute Disseminated Encephalomyelitis. Neurotherapeutics 13 : 84-95, 2016.
 
15) de Mol CL, et al : Incidence and outcome of acquired demyelinating syndromes in Dutch children : update of a nationwide and prospective study. J Neurol 265 : 1310-1319, 2018.
PubMed
P.232 掲載の参考文献
1) Langer-Gould A, et al : Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353 : 375-381, 2005.
 
2) Polman CH, et al : A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354 : 899-910, 2006.
PubMed
3) Plavina T, et al : Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76 : 802-812, 2014.
 
4) Ryerson LZ, et al : Natalizumab Extended Interval Dosing (EID) is Associated with a Reduced Risk of Progressive Multifocal Leukoencephalopathy (PML) Compared with Every-4-week (Q4W) Dosing : Updated Analysis of the TOUCH Prescribing Program Database (4419). Neurology 96 (15 Suppl) : 4419, 2021.
 
5) Scarpazza C, et al : Early diagnosis of progressive multifocal leucoencephalopathy : longitudinal lesion evolution. J Neurol Neurosurg Psychiatry 90 : 261-267, 2019.
PubMed
6) Alleg M, et al : Progressive multifocal leukoencephalopathy : MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML. Eur Radiol 31 : 2944-2955, 2021.
PubMed
7) Landi D, et al : No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology 88 : 1144-1152, 2017.
PubMed
8) Clifford DB, et al : Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis : lessons from 28 cases. Lancet Neurol 9 : 438-446, 2010.
PubMed
9) Himedan M, et al : Pathologic Findings of Chronic PML-IRIS in a Patient with Prolonged PML Survival Following Natalizumab Treatment. J Investig Med High Impact Case Rep 5 : 2324709617734248, 2017.
 
10) Stefoski D, et al : Treatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neurol 6 : 923-931, 2019.
PubMed
11) Cettomai D, et al : Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 66 : 255-258, 2009.
PubMed
12) Kappos L, et al : Natalizumab treatment for multiple sclerosis : updated recommendations for patient selection and monitoring. Lancet Neurol 10 : 745-758, 2011.
PubMed
13) Nakahara J, et al : Three cases of non-carryover fingolimod-PML : Is the risk in Japan increased? Neurol Neuroimmunol Neuroinflamm 6 : e559, 2019.
PubMed
14) Watanabe M, et al : Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod. J Neuroinflammation 17 : 206, 2020.
PubMed
15) Berger JR, et al : Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology 90 : e1815-e1821, 2018.
PubMed
16) Nishiyama S, et al : Fingolimod-associated PML with mild IRIS in MS : A clinicopathologic study. Neurol Neuroimmunol Neuroinflamm 5 : e415, 2018.
 
17) Berger JR : Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord 12 : 59-63, 2017.
PubMed
18) Jordan AL, et al : Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients. Mult Scler. 28 : 7-15, 2022.
PubMed
19) Gomez-Cibeira E, et al : Eculizumab-related progressive multifocal leukoencephalopathy. Neurology 86 : 399-400, 2016.
PubMed
20) Anada M, et al : Progressive Multifocal Leukoencephalopathy during Tocilizumab Treatment for Rheumatoid Arthritis. Intern Med 59 : 2053-2059, 2020.
PubMed

III 末梢神経脱髄疾患

P.239 掲載の参考文献
1) van Doorn PA, et al : Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol 7 : 939-950, 2008.
PubMed
2) Doets AY, et al : Regional variation of Guillain-Barre syndrome. Brain 141 : 2866-2877, 2018.
PubMed
3) ギラン・バレー症候群, フィッシャー症候群診療ガイドライン 2013 (日本神経学会監), 南江堂, 2013.
 
4) Leonhard SE, et al : Antecedent infections in Guillain-Barre syndrome in endemic areas of arbovirus transmission : A multinational case-control study. J Peripher Nerv Syst 26 : 449-460, 2021.
PubMed
5) Asbury AK, Cornblath DR : Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 27 (Suppl) : S21-24, 1990.
 
6) Sejvar JJ, et al : Guillain-Barre syndrome and Fisher syndrome : case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 29 : 599-612, 2011.
PubMed
7) Leonhard SE, et al : Diagnosis and management of Guillain-Barre syndrome in ten steps. Nat Rev Neurol 15 : 671-683, 2019.
PubMed
8) Yuki N, et al : Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 49 : 712-720, 2001.
PubMed
9) Kusunoki S, et al : Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol 39 : 424-431, 1996.
PubMed
10) Chiba A, et al : Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome : clinical and immunohistochemical studies. Neurology 43 : 1911-1917, 1993.
PubMed
11) Kaida K, et al : Ganglioside complexes as new target antigens in Guillain-Barre syndrome. Ann Neurol 56 : 567-571, 2004.
PubMed
12) Morikawa M, et al : Serological study using glycoarray for detecting antibodies to glycolipids and glycolipid complexes in immune-mediated neuropathies. J Neuroimmunol 301 : 35-40, 2016.
PubMed
13) Walgaard C, et al : Second intravenous immunoglobulin dose in patients with Guillain-Barre syndrome with poor prognosis (SID-GBS) : a double-blind, randomised, placebo-controlled trial. Lancet Neurol 20 : 275-283, 2021.
PubMed
14) Misawa S, et al : Safety and efficacy of eculizumab in Guillain-Barre syndrome : a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol 17 : 519-529, 2018.
PubMed
15) Wang Y, et al : IgG-degrading enzyme of Streptococcus pyogenes (IdeS) prevents disease progression and facilitates improvement in a rabbit model of Guillain-Barre syndrome. Exp Neurol 291 : 134-140, 2017.
 
16) Walgaard C, et al : Prediction of respiratory insufficiency in Guillain-Barre syndrome. Ann Neurol 67 : 781-787, 2010.
PubMed
17) Walgaard C, et al : Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology 76 : 968-975, 2011.
PubMed
18) Kuitwaard K, et al : Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome. Ann Neurol 66 : 597-603, 2009.
PubMed
19) Yamagishi Y, et al : Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 91 : 1339-1342, 2020.
PubMed
20) Martin-Aguilar L, et al : Serum neurofilament light chain predicts long-term prognosis in Guillain-Barre syndrome patients. J Neurol Neurosurg Psychiatry, 2020. (DOI : 10.1136/jnnp-2020-323899)
 
21) Kusunoki S, et al : Antiglycolipid antibodies in Guillain-Barre and Fisher syndromes : discovery, current status and future perspective. J Neurol Neurosurg Psychiatry 92 : 311-318, 2021.
PubMed
P.245 掲載の参考文献
1) Fisher M : An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 255 : 57-65, 1956.
PubMed
2) Ilyas AA, et al : Serum antibodies to gangliosides in Guillain-Barre syndrome. Ann Neurol 23 : 440-447, 1988.
 
3) Chiba A, et al : Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome : clinical and immunohistochemical studies. Neurology 43 : 1911-1917, 1993.
PubMed
4) 楠進, ほか : GBS疫学調査研究グループ. GBS疫学調査 : 本邦における脱髄型, 軸索型の頻度および臨床的特徴. 平成23年免疫性神経疾患に関する調査研究総括・分担研究報告書, p151-153, 2012.
 
5) Mori M, et al : Clinical features and prognosis of Miller Fisher syndrome. Neurology 56 : 1104-1106, 2001.
PubMed
6) Koga M, et al : Antecedent infections in Fisher syndrome : sources of variation in clinical characteristics. J Neurol 266 : 1655-1662, 2019.
PubMed
7) Chiba A, et al : Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res 745 : 32-36, 1997.
PubMed
8) Kusunoki S, et al : Anti-GQ1b IgG antibody is associated with ataxia as well as ophthalmoplegia. Muscle Nerve 22 : 1071-1074, 1999.
PubMed
9) Ito M, et al : Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum : clinical analysis of 581 cases. J Neurol 255 : 674-682, 2008.
 
10) Kuwabara S, et al : Special sensory ataxia in Miller Fisher syndrome detected by postural body sway analysis. Ann Neurol 45 : 533-536, 1999.
PubMed
11) Kaida K, et al : Ganglioside complexes as new target antigens in Guillain-Barre syndrome. Ann Neurol 56 : 567-571, 2004.
PubMed
12) Uchibori A, et al : Ca2+ -dependent anti-GQ1b antibody in GQ1b-seronegative Fisher syndrome and related disorders. J Neuroimmunol 298 : 172-177, 2016.
 
13) Uchibori A : Anti-GQ1b antibody : Recent topics. Clin Exp Neuroimmunol 12 : 158- 164, 2021.
 
14) Yoshikawa K, et al : Varied antibody reactivities and clinical relevance in anti-GQ1b antibody-related diseases. Neurol Neuroimmunol Neuroinflamm 5 : e501, 2018.
PubMed
15) 内堀歩, ほか : Ca2+依存性GQ1b抗体陽性症例の臨床像. 末梢神経 32 : 125-130, 2021.
Medical*Online
P.251 掲載の参考文献
1) Dyck PJ, et al : Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 50 : 621-637, 1975.
PubMed
2) Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 41 : 617-618, 1991.
 
3) Joint Task Force of the EFNS and the PNS ; European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy : report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. J Peripher Nerv Syst 15 : 1-9, 2010.
 
4) Van den Bergh PYK, et al : European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint Task Force-Second revision. J Peripher Nerv Syst 26 : 242-268, 2021.
PubMed
5) Katz JS, et al : Distal acquired demyelinating symmetric neuropathy. Neurology 54 : 615-620, 2000.
PubMed
6) Lewis RA, et al : Multifocal demyelinating neuropathy with persistent conduction block. Neurology 32 : 958-964, 1982.
PubMed
7) Shibuya K, et al : Reconstruction magnetic resonance neurography in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 77 : 333-337, 2015.
PubMed
8) Vlam L, et al : Multifocal motor neuropathy : diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol 8 : 48-58, 2011.
PubMed
9) Thomas PK, et al : Focal upper limb demyelinating neuropathy. Brain 119 (Pt 3) : 765-774, 1996.
 
10) Doneddu PE, et al : Atypical CIDP : diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J Neurol Neurosurg Psychiatry 90 : 125-132, 2019.
PubMed
11) Kuwabara S, et al : Different electrophysiological profiles and treatment response in 'typical' and 'atypical' chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 86 : 1054-1059, 2015.
PubMed
12) Allen JA, Lewis RA : CIDP diagnostic pitfalls and perception of treatment benefit. Neurology 85 : 498-504, 2015.
PubMed
13) Querol L, et al : Autoantibodies in chronic inflammatory neuropathies : diagnostic and therapeutic implications. Nat Rev Neurol 13 : 533-547, 2017.
PubMed
14) Koike H, et al : Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. J Neurol Neurosurg Psychiatry 88 : 465-473, 2017.
PubMed
15) Lozeron P, et al : Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy. Neurology 91 : e143-e152, 2018.
PubMed
P.257 掲載の参考文献
1) Dyck PJ, et al : Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 50 : 621-637, 1975.
PubMed
2) Van den Bergh PYK, et al : European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint Task Force-Second revision. J Peripher Nerv Syst 26 : 242-268, 2021./Eur J Neurol 28 : 3556-3583, 2021.
 
3) Dyck PJ, et al : Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 11 : 136-141, 1982.
PubMed
4) Dyck PJ, et al : Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 314 : 461-465, 1986.
PubMed
5) Hahn AF, et al : Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 119 (Pt 4) : 1055-1066, 1996.
 
6) Dyck PJ, et al : A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36 : 838-845, 1994.
PubMed
7) Allen JA, et al : Quantifying Treatment-Related Fluctuations in CIDP : Results of the GRIPPER Study. Neurology 96 : e1876-e1886, 2021.
PubMed
8) 慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン 2013 (「慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン」作成委員会編, 日本神経学会監), 南江堂, 2013.
 
9) Kuwabara S, et al : Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy : a multicentre, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry 88 : 832-838, 2017.
PubMed
10) Merkies ISJ, et al : Efficacy and safety of IVIG in CIDP : Combined data of the PRIMA and PATH studies. J Peripher Nerv Syst 24 : 48-55, 2019.
PubMed
11) Kuwabara S, et al : Different electrophysiological profiles and treatment response in 'typical' and 'atypical' chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 86 : 1054-1059, 2015.
PubMed
12) Doneddu PE, et al : Atypical CIDP : diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J Neurol Neurosurg Psychiatry 90 : 125-132, 2019.
PubMed
13) Nobile-Orazio E, et al : Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy : a randomised controlled trial. Lancet Neurol 11 : 493-502, 2012.
PubMed
14) Cocito D, et al : Subcutaneous vs. intravenous immunoglobulin in CIDP : pharmacokinetic and clinical response. J Peripher Nerv Syst 21 : 114-116, 2016.
PubMed
15) van Schaik IN, et al : Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 17 : 35-46, 2018.
PubMed
16) Racosta JM, et al : Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies : A meta-analysis. Muscle Nerve 55 : 802-809, 2017.
PubMed
17) van Schaik IN, et al : Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP : PATH extension study. Neurol Neuroimmunol Neuroinflamm 6 : e590, 2019.
PubMed
18) van Schaik IN, et al : Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study) : a double-blind, randomised, controlled trial. Lancet Neurol 9 : 245-253, 2010.
PubMed
19) van Lieverloo GGA, et al : Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. J Neurol 265 : 2052-2059, 2018.
PubMed
20) Eftimov F, et al : Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 78 : 1079-1084, 2012.
PubMed
21) Nobile-Orazio E, et al : Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. J Neurol Neurosurg Psychiatry 86 : 729-734, 2015.
PubMed
22) Muley SA, et al : Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 61 : 575-579, 2020.
PubMed
23) Godil J, et al : Refractory CIDP : Clinical characteristics, antibodies and response to alternative treatment. J Neurol Sci 418 : 117098, 2020.
PubMed
24) Dalakas MC : IgG4-Mediated Neurologic Autoimmunities : Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti-B Cell Therapies. Neurol Neuroimmunol Neuroinflamm 9 : 2022.
PubMed
25) Fatehi F, et al : Retrospective analysis of response to rituximab in chronic inflammatory demyelinating polyneuropathy refractory to first-line therapy. J Peripher Nerv Syst 26 : 469-474, 2021.
PubMed
26) Hu J, et al : Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy : a systematic review and meta-analysis. J Neurol 269 : 1250-1263, 2022.
PubMed
27) Kaplan A, Brannagan TH 3rd : Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 55 : 476-482, 2017.
PubMed
P.265 掲載の参考文献
1) Tang L, et al : Distinguish CIDP with autoantibody from that without autoantibody : pathogenesis, histopathology, and clinical features. J Neurol 268 : 2757-2768, 2021.
PubMed
2) Van den Bergh PYK, et al : European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint Task Force-Second revision. J Peripher Nerv Syst 26 : 242-268, 2021.
PubMed
3) Shelly S, et al : Neurofascin-155 Immunoglobulin Subtypes : Clinicopathologic Associations and Neurologic Outcomes. Neurology 97 : e2392-e2403, 2021.
PubMed
4) Martin-Aguilar L, et al : Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy. Neurol Neuroimmunol Neuroinflamm 9 : e1098, 2021.
PubMed
5) Ogata H, et al : Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol 2 : 960-971, 2015.
PubMed
6) Devaux JJ, et al : Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 86 : 800-807, 2016.
PubMed
7) Kadoya M, et al : IgG4 anti-neurofascin155 antibodies in chronic inflammatory demyelinating polyradiculoneuropathy : Clinical significance and diagnostic utility of a conventional assay. J Neuroimmunol 301 : 16-22, 2016.
PubMed
8) Zhang X, et al : Chronic inflammatory demyelinating polyneuropathy with anti-NF155 IgG4 in China. J Neuroimmunol 337 : 577074, 2019.
 
9) Delmont E, et al : Antibodies against the node of Ranvier : a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera. J Neurol 267 : 3664-3672, 2020.
 
10) Ogata H, et al : Optic, trigeminal, and facial neuropathy related to anti-neurofascin 155 antibody. Ann Clin Transl Neurol 7 : 2297-2309, 2020.
PubMed
11) Franques J, et al : Teaching NeuroImages : Cranial nerve hypertrophy in IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Neurology 88 : e52, 2017.
PubMed
12) Koike H, et al : Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. J Neurol Neurosurg Psychiatry 88 : 465-473, 2017.
PubMed
13) Ogata H, et al : Unique HLA haplotype associations in IgG4 anti-neurofascin 155 antibody-positive chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 339 : 577139, 2020.
PubMed
14) Ogata H, et al : Intrathecal cytokine profile in neuropathy with anti-neurofascin 155 antibody. Ann Clin Transl Neurol 6 : 2304-2316, 2019.
PubMed
15) Manso C, et al : Anti-Neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo. J Clin Invest 129 : 2222-2236, 2019.
PubMed
16) Dubey D, et al : Contactin-1 autoimmunity : Serologic, neurologic, and pathologic correlates. Neurol Neuroimmunol Neuroinflamm 7 : 2020.
PubMed
17) Hashimoto Y, et al : Chronic Inflammatory Demyelinating Polyneuropathy With Concurrent Membranous Nephropathy : An Anti-paranode and Podocyte Protein Antibody Study and Literature Survey. Front Neurol 9 : 997, 2018.
PubMed
18) Wald A, et al : Overlap of Bullous, Anti-Laminin-332, and Anti-p200 Pemphigoid With Concomitant Anti-Contactin-1-Positive Inflammatory Polyneuropathy Treated With Intravenous Immunoglobulins as a Manifestation of Epitope Spreading. JAMA Dermatol 155 : 631-633, 2019.
PubMed
19) Kouton L, et al : Electrophysiological features of chronic inflammatory demyelinating polyradiculoneuropathy associated with IgG4 antibodies targeting neurofascin 155 or contactin 1 glycoproteins. Clin Neurophysiol 131 : 921-927, 2020.
PubMed
20) Manso C, et al : Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects. Brain 139 : 1700-1712, 2016.
PubMed
21) Le Quintrec M, et al : Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy. Kidney Int 100 : 1240-1249, 2021.
PubMed
22) Shimizu S, et al : Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE) : Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial. JMIR Res Protoc 9 : e17117, 2020.
PubMed
23) Fukami Y, et al : Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients. J Neurol 268 : 3835-3844, 2021.
PubMed
24) Doppler K, et al : Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy. Brain 139 : 2617-2630, 2016.
PubMed
25) Cortese A, et al : Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP : Clinical relevance of IgG isotype. Neurol Neuroimmunol Neuroinflamm 7 : e639, 2019.
PubMed
26) Pascual-Goni E, et al : Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy. Brain 144 : 1183-1196, 2021.
 
27) Delmont E, et al : Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. Brain 140 : 1851-1858, 2017.
PubMed
28) Xie C, et al : From PNS to CNS : characteristics of anti-neurofascin 186 neuropathy in 16 cases. Neurol Sci 42 : 4673-4681, 2021.
PubMed
29) Stengel H, et al : Anti-pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathy. Neurol Neuroimmunol Neuroinflamm 6 : e603, 2019.
PubMed
30) Fehmi J, et al : IgG1 pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality. J Neurol Neurosurg Psychiatry 92 : 1089-1095, 2021.
PubMed
P.272 掲載の参考文献
1) Zee PC, et al : Peripheral nervous system involvement in multiple sclerosis. Neurology 41 : 457-460, 1991.
PubMed
2) Bouchard C, et al : Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 52 : 498-503, 1999.
PubMed
3) Ogata H, et al : A nationwide survey of combined central and peripheral demyelination in Japan. J Neurol Neurosurg Psychiatry 87 : 29-36, 2016.
PubMed
4) Cortese A, et al : Combined central and peripheral demyelination : Clinical features, diagnostic findings, and treatment. J Neurol Sci 363 : 182-187, 2016.
PubMed
5) Wang YQ, et al : The clinical features of combined central and peripheral demyelination in Chinese patients. J Neuroimmunol 317 : 32-36, 2018.
PubMed
6) Hou X, et al : The clinical features of combined central and peripheral demyelination and antibodies against the node of Ranvier. Mult Scler 28 : 453-462, 2022.
PubMed
7) Van den Bergh PYK, et al : European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint Task Force-Second revision. J Peripher Nerv Syst 26 : 242-268, 2021.
PubMed
8) Kawamura N, et al : Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology 81 : 714-722, 2013.
PubMed
9) Devaux JJ, et al : Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 86 : 800-807, 2016.
PubMed
10) Ogata H, et al : Optic, trigeminal, and facial neuropathy related to anti-neurofascin 155 antibody. Ann Clin Transl Neurol 7 : 2297-2309, 2020.
PubMed
11) Verghese A, et al : Optic Nerve Demyelination in IgG4 Anti-Neurofascin 155 Antibody-Positive Combined Central and Peripheral Demyelination Syndrome. J Cent Nerv Syst Dis 13 : 11795735211039913, 2021.
PubMed
12) Kitada M, et al : Acute combined central and peripheral demyelination showing anti-aquaporin 4 antibody positivity. Intern Med 51 : 2443-2447, 2012.
PubMed
13) Warabi Y, et al : Abnormal nerve conduction study findings indicating the existence of peripheral neuropathy in multiple sclerosis and neuromyelitis optica. Biomed Res Int 2013 : 847670, 2013.
PubMed
14) Takai Y, et al : Two cases of lumbosacral myeloradiculitis with anti-aquaporin-4 antibody. Neurology 79 : 1826-1828, 2012.
PubMed
15) Rinaldi S, et al : Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders. Neurol Neuroimmunol Neuroinflamm 8 : 2021.
PubMed
16) Nakamura T, et al : Myelin oligodendrocyte glycoprotein-IgG-positive, steroid-responsive combined central and peripheral demyelination with recurrent peripheral neuropathy. Neurol Sci 42 : 1135-1138, 2021.
PubMed
17) Shima S, et al : Anti-neutral glycolipid antibodies in encephalomyeloradiculoneuropathy. Neurology 82 : 114-118, 2014.
PubMed
P.277 掲載の参考文献
1) Joint Task Force of the EFNS and the PNS : European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revision. J Peripher Nerv Syst 15 : 185-195, 2010.
PubMed
2) Schachner M, Bartsch U : Multiple functions of the myelin-associated glycoprotein MAG (siglec-4a) in formation and maintenance of myelin. Glia 29 : 154-165, 2000.
PubMed
3) Hamada Y, et al : Binding specificity of anti-HNK-1 IgM M-protein in anti-MAG neuropathy : possible clinical relevance. Neurosci Res 91 : 63-68, 2015.
PubMed
4) Stalder AK, et al : Immunoglobulin M deposition in cutaneous nerves of anti-myelin-associated glycoprotein polyneuropathy patients correlates with axonal degeneration. J Neuropathol Exp Neurol 68 : 148-158, 2009.